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Biodegradable nanoparticles that have a functionalizable surface are appealing 
candidates for new vaccine adjuvant materials. Here we investigated the effect of 
chemically modified phytoglycogen, a dendrimer-like α-D-glucan nanoparticle called 
Nano-11, on the immune cells and its potential as a new generation adjuvant.  
Nano-11 has a diameter between 30 nm to 110 nm and a surface charge of 
between 15 mV to 20 mV across a range of pH values. This enables the particles to 
adsorb a large amount of negatively-charged antigens on the surface. Cytotoxicity 
assays revealed that Nano-11 induced low lactate dehydrogenase (LDH) release from 
bone marrow derived dendritic cells (BMDCs), supporting its safety for vaccine 
formulation.  
After adsorbing negatively-charged antigens, Nano-11 can facilitate their delivery 
into BMDCs in vitro. Coincubation of Nano-11 with BMDCs directly activated the cells by 
increasing the expression of costimulatory molecules CD80 and CD86 on the cell surface 
and inducing the secretion of IL-12p40. Nano-11 activated a cytoplasmic multi-protein 




the secretion of proinflammatory cytokine IL-1β. This is likely due to the release of 
lysosomal enzyme cathepsin B into cytoplasm because treatment of BMDCs with 
cathepsin B inhibitor CA-074 decreased the amount of IL-1β detected in the supernatant. 
The effect of Nano-11 on antigen presenting cells (APCs) translated into good 
adjuvanticity in vivo. Formulation of Nano-11 with two different antigens, ovalbumin 
(OVA) and recombinant protective antigen (rPA), resulted in significantly enhanced 
immune response in mice.   
Utilizing a whole mouse imaging system, the distribution of fluorescently labeled 
Nano-11 was followed after intramuscular injection. It was found to be initially retained 
at the injection site and gradually cleared over the course of three weeks. A detailed 
dissection of the inflammatory response at the injection site through 
immunofluorescence revealed that Nano-11 induced a strong but temporary response, 
which recruited neutrophils, monocytes, eosinophils, macrophages, and APCs to the 
vicinity of the nanoparticles. Among the recruited cells a Mac-2+ macrophage population 
phagocytosed the majority of the Nano-11, preventing its long term depot in the muscle. 
Cell-mediated transport of Nano-11 to the draining lymph node (dLN) was observed, 
dominated by migratory dendritic cells (MigDCs). Nano-11 also promoted the delivery of 
antigen to dLN and enhanced uptake by MigDCs.  
BMDCs internalized Nano-11 through multiple mechanisms including actin-
mediated phagocytosis, macropinocytosis, clathrin-mediated endocytosis, and caveolae-




and fused with lysosomes within 60 min and no exocytosis of intracellular Nano-11 was 
observed.  
Collectively, this study demonstrated that phytoglycogen based nanoparticle 
Nano-11 is an effective adjuvant. It works by improving antigen targeting to professional 
APCs and directly stimulating the immune system. Nano-11 also demonstrated a good 
safety record. Its preparation is relatively inexpensive and easy to scale up comparing 
with other synthetic nanoparticles. All these features make Nano-11 an attractive 






CHAPTER 1 LITERATURE REVIEW 
1.1 Vaccines 
Vaccines are one of the most successful interventions of modern medicine and 
represent the most economical and effective ways to protect general population from 
infectious diseases 1. They were first developed in 1796 by Edward Jenner, who 
discovered that administration of cowpox virus to patients could stimulate specific 
immunity toward smallpox and protect them from future epidemics 1,2. This method was 
so effective and that within a few years, it was practiced throughout Europe. Since the 
virus used in smallpox inoculation is a close relative of cowpox called Vaccinia, this 
method is called vaccination 3.  
Vaccination has since then been applied to other microbes and the list of 
prophylactic vaccines continues to grow. Currently, there are more than 70 vaccines in 
use protecting the public from around 30 pathogens, including tetanus, pertussis, 
diphtheria, tuberculosis, influenza, polio, hepatitis, human papillomavirus (HPV), etc. 1. 
The triumph of modern vaccination is the eradication of smallpox in the world by the 






During the early years of vaccine development, commercialized vaccines were 
mostly attenuated whole pathogens or toxins. Although highly immunogenic, the 
concerns for their toxicity have driven vaccinologists to search and develop safer and 
more purified antigens 5,6. It is also desired that these rationally designed antigens will 
induce a more protective immune response. 7. Nowadays, the big trend of vaccine 
industry is the movement toward subunit vaccines, which are formulated with only 
defined components of microbes, including proteins, peptides, and nucleic acids 1.   
In addition to purified proteins, advances in recombinant DNA technology 
enabled the synthesis of pure antigenic proteins. The vectors are usually expressed in 
bacteria or yeast. Such technology has led to the production of for example hepatitis B 
virus (HBV) surface antigen and HPV antigen, both have been applied in marketed 
vaccines 8. A new concept called “reverse vaccinology” has further empowered impact 
of recombinant protein antigens. It involves an initial mining of genomic information of 
the organism to identify potentially antigenic proteins. These candidates are then tested 
in vitro and in vivo to pick the most promising ones for further development. This has 
already led to a marketed meningococcal vaccine 7. Comparing with recombinant 
proteins, the other two forms of subunit vaccines, peptide vaccines and nucleic acid 
vaccine are currently less common. Peptide vaccines are comprised of small peptides 
that are identified to be specific antibody-binding sites (epitopes) within an antigenic 
protein 9,10. Comparing with recombinant proteins, they have the advantage of easier 
production and enhanced stability 8. However, currently there is still no peptide vaccine 





designed plasmid DNA or messenger RNA could hijack the host expression system to 
produce antigens in situ. This could imitate a natural infection and lead to an immune 
response against the encoded antigen. Up to now the application of nucleic acid 
vaccines in human is very limited, mainly due to low expression efficiency of antigenic 
proteins in the humans and safety concerns of potential integration of the administered 
nucleic acid into host genome 8,11. 
Despite tremendous progress, there are several challenges for vaccinologists to 
solve, including developing effective vaccines for pathogens against which there are still 
no effective vaccines like human immunodeficiency virus (HIV) and malaria; decreasing 
the number of dosages required for certain vaccines to improve patient compliance; 
enhancing the immune response in susceptible populations including infants, aged 
adults, and immunocompromised individuals with an immature or suboptimal immune 
system; widening the type of immune response stirred by current vaccines to cell 
mediated immune responses, which may be more effective against intracellular 
microbes 7,8,12. In addition, the big trend of moving toward subunit vaccines has caused 
an issue for vaccine developers since these purified antigens typically exhibit low 
immunogenicity by themselves, reducing the efficacy of vaccines 13.  
1.2 Adjuvants 
One of the main reasons subunit vaccines are less immunogenic is that a lot of the 
stimulatory molecules present in whole pathogen vaccines are lost during the 
purification process, or just not expressed in the first place in the case for recombinant 





recognized by specific pattern recognition receptors (PRRs) on innate immune cells and 
play a large role in the initiation and maintaining of the immune protection 13–15. When 
such stimulatory molecules are not present in vaccines, additional materials called 
adjuvant (from Latin adjuvare meaning “to help”) are often included in the vaccine 
formulations to induce a more potent immune response 14,16,17. With the overall 
transition to subunit antigens, more and more vaccines include adjuvants into their 
formulations. By 2012, more than half of the marketed human vaccines were 
adjuvanted vaccines 18. Adjuvants replace the necessity of natural pathogens to alert the 
innate immune response and induce a transient and mild inflammatory response at the 
site of injection. The inflammatory response recruits immune cells to the vaccination 
site and create an immunostimulatory microenvironment that could drive the following 
vaccine-specific adaptive immune response 19. The application of adjuvants has further 
applications. The immunostimulatory effect of adjuvant has a considerable impact on 
the speed and strength of the immune response which can result in rapid immunity in 
time of need and extend the immune protection to certain populations like infants, 
elderly people, and immunocompromised individuals. Adjuvants can also reduce the 
amount of antigen required for a vaccine, which would make a big difference in 
situations like an unexpected pandemic and the amount of antigen available is limited, 
for example an influenza outbreak. Adjuvants also affect the type of immune response, 
which helps to activate the most effective arm of adaptive immunity in response to the 





The most commonly used vaccine adjuvants are aluminum-containing adjuvants. 
They were discovered in 1926 by A. Glenny 20 and have since then been extensively 
utilized in human vaccines. Decades of use have proven them to be effective, safe, and 
well tolerated 21,22. The main limitation of aluminum adjuvants is its rigid requirement of 
a nonfreezing condition during storage and transportation, adding additional cost for 
distribution, and its inefficiency in inducing Th1 and cell-mediated immune responses 23. 
The other adjuvant that has been applied in large number is an oil in water emulsion 
called MF59. It is formulated as a component of a seasonal influenza vaccine marketed 
in Europe and was proven to enhance the immune response in the elderly, making it the 
first demonstration that proper utilization of adjuvants could help optimize the immune 
response in certain populations 12. However, similar to aluminum adjuvants, it is also a 
poor inducer of Th1 and cell-mediated responses.  
Modern vaccine development has moved into the era of rational design involving 
careful selection of both antigen and adjuvant 24,25. However, compared with antigen 
development, progress in adjuvants is considerably slower, with the above mentioned 
two adjuvants being the main players in the field. Given the number of challenges facing 
vaccinologists and the inability of aluminum adjuvants and MF59 in inducing certain 
arms of the immune response, there is an urgent need for novel and more effective 
vaccine adjuvants. A variety of materials are currently under study as next generation 
adjuvants. It is generally accepted that the old empirical ways of adjuvant development 
without a full appreciation of its mechanism should be avoided. Modern adjuvants tend 





before their formulation in vaccines 14. These candidate materials can generally be 
divided into two groups: antigen delivery vehicles and immunostimulatory molecules 8. 
Antigen delivery vehicles are usually particulate in nature that can associate with 
antigens to ease their delivery to antigen presenting cells (APCs), while 
immunostimulatory molecules are capable of targeting specific receptors on innate 
immune cells, often agonists of PRRs 8,14. 
1.3 Nanotechnology in adjuvants 
Over the past few decades, there has been an increasing interest in applying 
nanotechnology to the design of next generation vaccine adjuvants 6,26. Modern 
nanoengineering enables the production of particles in the nanometer range often with 
a diameter between 20 and 200 nm. Particles in this size range are comparable to many 
intracellular pathogens, and can be easily endocytosed by many immune cells, making 
them suitable for vaccine delivery. Indeed, as early as 1976 a polymeric micelle particle 
with a diameter of 80 nm was already found to increase the antibody response to 
coinjected antigen in guinea pigs 27. However, back then further application of 
nanoparticles in vaccines were deterred over the concerns over their nondegradable 
nature. The subsequent development of biodegradable nanoparticles together with 
different physical and chemical methods to functionalize their surface not only made 
possible the administration of nanomaterials in human but also allowed them to be 
tailored for different needs 28. This paved the way for their application in vaccine 
formulation and today several nanomaterials or nanosized vaccines have been approved 





Several features made nanoparticles an ideal platform for building the next 
generation vaccines. The first feature is safety. Most of the current nanoparticles are 
built with defined components and with a certain level of understanding of their 
biological effect on the host. This matches with the current bottom-to-top philosophy of 
rational vaccine design to ensure the highest clinical safety. Current vaccine antigens are 
often microbial membrane, cell wall, or capsid components like proteins, glycoproteins, 
and polysaccharides. These membrane antigens are usually less immunogenic and tend 
to diffuse away rapidly from the injection site without much time to interact with the 
immune system. Combining them with a defined nanoparticle similar in size as their 
original anchored microbe would be a sound but also one of the safest way to present 
these antigens in their natural form to the immune cells 6,30.  On the other hand, the 
flexible designing of the nanoparticles also made specific targeting of the antigens 
possible. This can be achieved by either changing physical properties like size and shape, 
or by functionalization of the particle surface with certain materials or receptor agonists 
[3,30]. Different methods to combine antigens and nanoparticles with various strengths 
of association can control the rate of antigen release from the injection site to allow 
optimal interaction between antigens and recruited immune cells 26. Last but not least, 
nanoparticles can not only serve as a vaccine delivery system but can work as an 
immunostimulator as well. The particulate nature and similarity in size to pathogen by 
itself may serve as a PAMP to activate APCs 4,30. Meanwhile nanoparticles can also 
deliver canonical immunostimulators like PRR agonists along with the antigens to 





Nanoparticles have even a broader application than traditional injectable 
vaccines. Their nanosized nature opened doors for potential future administration of 
vaccines through oral or nasal routes. These needle-free vaccines would likely have a 
higher compliance for inoculation in the general public, especially among young children. 
The alternative routes boost not only systemic, but mucosal protection as well. In this 
way, a lot of contagious pathogens like influenza can be expelled at their point of 
contact at the host, rather than having to wait till the infection is already established 4. 
Nanoparticles can also find their way in more than prophylactic vaccines. In recent years, 
manipulation of the immune system through vaccination has also been employed in 
areas like treatment of cancer. With their potential in targeting and activating APCs, 
nanoparticles are excellent candidates to help launch immune attacks against tumor 
cells 33–35.  
Some of the major nanosized adjuvants in use or under investigation are discussed 
below. A list of major nanoparticles adjuvants and their feathers like size, surface charge, 
and biodegradability is provided in Table 1.1.  
1.4 Nanoparticle adjuvants 
1.4.1 Polymeric NP 
The most commonly studied polymeric nanoparticles nowadays are poly(D,L-lactide-
coglycolide)(PLG) 36, poly(L-lactic acid)(PLA)37, and poly(D,L-lactic-coglycolic acid)(PLGA) 
38–42. Among them PLGA nanoparticles are the most promising candidate due to their 
superior biocompatibility and biodegradability 43,44. PLGA nanoparticles are usually 





encapsulated during the process, and by adjusting the composition of the copolymers, 
the release kinetics of the loaded antigens can be controlled to achieve the highest 
immunogenic efficiency  6. However, such method seemed to destabilize the antigen 
due to the harsh environment during the encapsulation process 47. Another issue 
preventing the antigen-encapsulating PLGA particles to be applied in clinical vaccines is 
the cost. Since antigens are involved during PLGA synthesis, a special aseptic 
manufacturing environment is required during the production of the nanoparticle, this 
makes the PLGA  encapsulation scheme relatively expensive 14. Direct adsorption of 
antigen onto pre-formed polymeric nanoparticles have been investigated and it was 
shown that absorbed antigens retained their structural integrity 48,49, although 
comparing with their encapsulated counterparts, absorbed antigens seemed to have 
reduced ability to activate the cell-mediated immune response 50. Even then, these 
polymeric nanoparticles continue to attract considerable interest among vaccinologists 
and the scaling up of the process for potential mass production in the future is currently 
under way 51. 
PLGA nanoparticles serve as an adjuvant through multiple mechanisms. First, 
since they can release the antigens in a delayed fashion, it would give the immune 
system longer time to interact with the antigens, the so-called “depot effect” 38,44. On 
the other hand, either encapsulating or absorbing antigens by PLGA nanoparticles can 
convert them to a particulate form, which would increase the uptake of antigens by 
APCs, especially dendritic cells (DCs) 52. Meanwhile, although often underappreciated, 






since subtle changes in the composition of PLGA would alter adjuvanticity, with 
increased hydrophobicity usually inducing a stronger immune response. 53. As an 
adjuvant, PLGA nanoparticles induce a humoral immune response with the systemic 
antibody titers comparable to aluminum adjuvants 44. However, PLGA particles can also 
activate a cell-mediated immune response in mice 54,55, although the level of the 
response was suboptimal compared with another nanosized adjuvant,  liposome 54,55, 
and the activation of the cell-mediated response was not replicated in non-human 
primates 56. 
Though currently there is no vaccine formulated with PLGA nanoparticles, they 
have been tested with several different vaccines including Plasmodium vivax 57, HBV 37, 
Bacillus anthracis 41, influenza 58, Leishmania 59, and have been used to induce an anti-
cancer immune response 60. In addition, PLGA may also serve as a good mucosal vaccine 
delivery system since it can offer protection and slow release of encapsulated antigens 
and facilitate the delivery of antigens to M-cells in the mucosal-associated lymphoid 
tissue (MALT) when it is administered orally or intranasally 44,61,62. An HBV vaccine 
formulated with PLGA has been tested through the pulmonary route 37. 
1.4.2 Aluminum-containing adjuvants 
Compared with other novel adjuvants under investigation now, aluminum-containing 
adjuvants, also called aluminum adjuvants or aluminum salts, are considered “old school” 
and people would not normally connect them with nanotechnology. However as new 






detail below, it was found that the primary components of aluminum adjuvants are 
actually in the nanoscale, so aluminum salts are indeed nanosized adjuvants.   
Originally aluminum adjuvant was prepared together with the antigens, resulting 
the precipitation of the antigens on the newly formed adjuvants 20,63,64. However, these 
“aluminum-precipitated” vaccines nowadays have been largely replaced by simply 
mixing antigens with preformed commercially available products before use (so called 
“aluminum adsorbed” vaccines) to ease the production process and achieve higher 
reproducibility 14.  
There are currently two types of commercially available aluminum adjuvants, 
each with different physical and chemical properties 22. The first one is commercially 
called aluminum hydroxide (AH) although chemically it is actually aluminum 
oxyhydroxide, Al(O)OH. Its primary structure consists of  needle-like nanoparticles about 
10 nm in length 65. These primary particles then aggregate into crystalline microparticles 
about 17 µm  in diameter 66. The point-of-zero-charge (PZC) of AH is 11.4, resulting in a 
positive surface charge at neutral pH, enabling it to electrostatically attract negatively 
charged antigens. The other commercially available aluminum adjuvant is aluminum 
phosphate (AP), which is chemically aluminum hydroxyphosphate, Al(OH)x(PO4)y, with “x” 
and “y” varying depending on the preparation methods. The primary structure of AP is 
50 nm sized “plates” 67, which then form amorphous loose aggregates of about 3 μm in 
diameter 66. The PZC of AP is around 5, leading to a negative surface charge at neutral 






primary structures, the surface area of AH and AP are extremely high, giving them a high 
antigen-binding capacity 22. 
As an “adsorbent” for antigens, aluminum adjuvants bind to antigens through 
different mechanisms including ligand exchange, electrostatic attraction, hydrophobic 
and van der Waals forces 68. Among them ligand exchange and electrostatic attraction 
are the stronger ones 69. Electrostatic attraction is formed when the adjuvant and 
antigen have opposite charges. Ligand exchange happens when phosphate groups on 
antigens displace the hydroxyls on the AH surface, resulting in a covalent bond-like 
binding 68. It is the strongest attractive force between aluminum adjuvants and antigens 
and shows the least reversibility, even upon exposure to interstitial fluid 70. The level of 
ligand exchange binding between AH and phosphate group-containing antigens can be 
adjusted by pretreatment of AH with phosphate buffers, which reduces the amount of 
hydroxyl groups available on the adjuvant surface for ligand exchange binding 68. It is 
generally accepted that antigens need to bind to aluminum adjuvants for optimal 
immune response, although there are reports that adsorption of antigens is not 
necessary 71, and in some cases too tight binding may even have a detrimental effect on 
the immunopotentiation 72. Nevertheless, for clinical vaccines antigens are usually 
expected to be adsorbed onto aluminum adjuvants 73.  
Aluminum adjuvants mainly induces a Th2 response in mouse models 23,74, but 
activation of Th17 response has also been reported 75,76. In human beings,  the response 






How aluminum adjuvants work is considered a century old mystery. Originally 
they were believed to work by retaining the absorbed antigens at the injection site for 
an extended period of time to prolong their exposure to the immune cells (depot effect) 
77 . This was suggested by the observation that ground injection sites excised from 
immunized guinea pigs up to seven weeks after administration could be used to 
immunize other guinea pigs 78. This proved antigens were indeed retained at the 
injection site.  However, this theory was then first challenged by Holt, who 
demonstrated that removal of the injection site 14 days after administration had no 
effect on the following immune response 79, indicating long time retention of antigen is 
not necessary. Later, it was demonstrated that absorbed tetanus toxoid quickly eluded 
from AP after administration and about 80% left the injection site within the first four 
hours 80. More recently, a research group even went further and removed the injection 
site as early as two hours post immunization and found the response was not affected, 
based on which the authors concluded that depot formation is not required for 
aluminum adjuvanticity 81. Judging from these findings, vaccinologists now agree that 
antigen depot is not the sole mechanism by which aluminum adjuvants boost the 
immune response.  
Aluminum adjuvants also recruit many inflammatory cells to the injection site 82. 
More detailed studies revealed that the inflammation reaction started several hours 
after administration and can last at least seven days 83–86. In one study, inflammation 
was also observed months after administration at the injection site in non-human 






monocytes, and DCs. Along with the infiltration of immune cells, secretion of 
chemokines like CCL2, CCL3, CCL4, and CXCL8 was detected at the injection site 88. In 
addition, the recruited cells, especially APCs, were found to be able to pick up the 
antigen and transport it to the draining lymph node (LN) 83. Hence, in contrast to the 
canonical view of passively “holding on” to antigens, aluminum adjuvants take an active 
role initiating a robust immune response, both at the innate and adaptive level. Now the 
question is which molecule, pathway, or step is critical for such immunopotentiation?  
When the critical role of toll-like receptors (TLRs) in pathogen recognition and 
the following transcriptional events leading to the inflammatory response was first 
appreciated, it was speculated that they might be the target of aluminum adjuvants. 
However, utilizing MyD88 and TRIF double deficient mice, it was confirmed that TLRs are 
not required for their adjuvanticity 89. In 2008, several papers came out about the same 
time pointing out that aluminum adjuvants actually activate a proinflammatory 
intracellular machinery called NLRP3 inflammasome 90–94. NLRP3 inflammasome is a 
multiprotein complex made up of the cytoplasmic pattern recognition receptor NLRP3, 
an adaptor protein called apoptosis-associated speck-like protein (ASC), and caspase-1.  
Uptake of aluminum adjuvants by APCs can lead to the destabilization of the aluminum 
containing lysosomes and the release of lysosomal cathepsin B into cytoplasm 93. 
Released cathepsin B may induce assembly of functional NLRP3 inflammasome 
machinery, which cleaves the pro-IL-1β and pro-IL-18 in the cytoplasm into their active 
forms and secret them as potent proinflammatory cytokines 95. This is the first pathway 






consistent in vitro data that aluminum adjuvants do activate NLRP3 inflammasome, the 
importance of this pathway for aluminum adjuvanticity in vivo remains controversial. 
Some groups found the NLRP3 inflammasome to be indispensable 90,92,94, while others 
found that it was not necessary for an optimal response 84,96,97. The inconsistency in 
their results may reflect differences in experimental conditions like the type of 
aluminum adjuvants and antigens used, dosage, mouse strain, and immunization 
schedule. Nevertheless, these are still no consensus among the scientific community 
whether inflammasome activation is a critical step for aluminum adjuvanticity.  
Other molecules and pathways have been discovered to be associated with 
aluminum adjuvanticity. Administration of aluminum adjuvant induced cell damage and 
release of uric acid. Uric acid is likely to be involved in immunopotentiation since uricase 
treated mice had decreased proliferation of antigen-specific T cell in the draining LN 85, 
and they could not be sensitized by aluminum adjuvants to establish allergic airway 
disease any more 98. Injection of aluminum adjuvants can also induce the release of DNA 
from the necrotic cells at the injection site. DNA has an immunopotentiating effect itself 
and administration of DNAse along with aluminum adjuvant reduced the humoral 
immune response 99, suggesting DNA may contribute to the adjuvant effect. However, a 
recent study revealed that the commercial DNAse used in the above experiment was 
contaminated with proteases, so the reduction of humoral responses may be actually 
due to degradation of the antigen. The suggested role of released DNA in aluminum 
adjuvanticity will need to be taken with caution 100. Another study proposed a new way 






and led to the reassortment of lipids along with aggregation of lipid rafts. Such 
rearrangement of membrane lipids activated the syk kinase and phosphoinositide-3 
kinase (PI3K) pathways 101. The authors of the study also claimed that only the antigen 
was endocytosed by DCs while the adjuvant particles were not taken up by the cells. 
This is, however, not consistent with several studies identifying aluminum adjuvants 
inside APCs both in vitro and in vivo 66,86,102. Damage to phagolysosomes caused by 
aluminum adjuvants may activate p38 MAP kinas pathways, which would in the end 
lead to the release of prostaglandin E2 (PGE2).  Secreted PGE2 may serve as a secondary 
signal since prostaglandin E synthase-deficient mice were found to be deficient in 
producing antigen-specific IgE 103. Additional mechanisms that have been reported 
include the involvement of type II nature killer T cells in facilitating the development of 
humoral responses 104 , role of IL-33 as a secondary signal for aluminum adjuvants 105, 
and the necessity of CD300a phosphatidylserine immunoreceptors expression on 
recruited DCs to induce antigen-specific IgE 106. 
The multitude of potential mechanisms underlying the immunostimulatory 
effect of aluminum adjuvants reflects increased awareness of the interconnection 
between innate immunity and the adaptive immune response, and the ever growing list 
of tools and technologies available to immunologists. It is likely that aluminum adjuvants 
work by activating several pathways either directly or indirectly without a single 
dominant force 14.   
Aluminum adjuvants are currently the most commonly used adjuvant in human 






anthrax, influenza, HPV, pneumococcus, and meningococcus 14,21,22. Aluminum adjuvant 
are also being used in immunotherapy for allergy symptoms and have been tested in 
autoimmune disease immunotherapy 14,22. They are also used as a delivery system in the 
formulation of second generation adjuvants, which are composed of delivery systems 
along with an immunostimulator, for example TLR agonists. Indeed, the first approved 
clinical vaccine containing a second generation adjuvant is a HPV vaccine: Cervarix® by 
GlaxoSmithKline. Its adjuvant is called AS04, composed of AH and a TLR agonist 
monophosphoryl lipid A (MPL) 14,107.   
In addition to the traditional aluminum adjuvants that aggregate into micro-sized 
particles, Li and colleagues managed to produce AH that form particles only around 100 
nm in size 108. This nano-sized aluminum adjuvant induced a much stronger antibody 
response than their microparticle peers, while the inflammatory reaction induced at the 
injection site was milder than the microparticles. The superior adjuvanticity of AH 
nanoparticles were believed to be at least in part due to enhanced APC uptake 108.  
During 90 years of usage, aluminum demonstrated an excellent safety record. 
The most common adverse effect is a local inflammatory response at the injection site. 
The symptoms include swelling, pain and redness of the skin. However, these reactions 
are usually mild and transient 22. A muscle disease called macrophage myofasciitis was 
reported in those had been administered aluminum adjuvanted vaccine 109. The 
symptoms included muscle weakness, arthralgia, and fever. Biopsy of the injection site 
revealed accumulation of macrophages with detectable intracellular AH. Nevertheless, 






symptoms 110.  One last inconvenience about aluminum adjuvanted vaccines is their 
rigid requirement for a nonfreezing temperature during storage and transportation 
since they are very sensitive to freezing and drying 111. This adds additional cost to their 
distribution.   
1.4.3 Virus-like particles 
Another form of nanoparticles that are applied in vaccines is virus-like particles (VLPs) 
112. They are virus membrane proteins self-assembled into a nanosized complex 
displaying a high density of repetitive epitopes 111,113–115. They are between 20nm to 
800nm in size 113,114,116. Unlike real viruses, VLPs do not contain any genetic material, so 
they do not replicate once administered 6. Genes for viral integrase are also depleted 
during the production of VLPs to prevent potential integration of viral genomic 
information into the host in infected recipients 117. VLPs are immunogenic since they 
harness the feature of naturally selected size and antigen arrangement of viruses, and 
can have some internal adjuvanticity even by themselves 26,113,118. 
Several systems that are amenable for scaling up have been developed for VLP 
production. They are mostly in vitro cell culture systems and based on a report of the 
174 successfully developed VLPs, the most commonly utilized ones include insect 
systems (28%), bacterial systems (28%), and yeast systems (20%) 116,117. Once produced, 
VLPs will need to be purified before formulation into vaccines 4. One of the popular 
expression systems nowadays is baculovirus in insect cells. Baculovirus does not infect 






can also produce both enveloped and non-enveloped VLPs 120. In this system, a gene 
coding for a dispensable protein component of the viral membrane is displaced with the 
gene coding for the protein of interest. The modified vector is then introduced into 
insect cells by baculovirus and the protein introduced will be produced with the host cell 
machinery and self-assemble into VLPs 121. A disadvantage of this system is that proteins 
expressed in insect cell will lack some of the post-translational modifications that usually 
happen in mammalian cells 6. To overcome this problem, “humanized” insect cells have 
been developed, which constitutively express relevant genes responsible for 
modification of expressed proteins in mammalian cells, like galactosylation and 
glycoprotein sialylation 122–125. Another disadvantage of this system is that insect cells 
tend to be lysed by baculovirus within a couple of days after the transfection, which may 
affect the yield and damage the protein of interest 6. To solve this issue, non-lytic strains 
of baculovirus have been developed, considerably decreasing the host cell lysis 126.  A 
further improvement of VLPs manufacturing is the introduction of a cell-free assembly 
system 127–131.  The traditional way of producing VLPs inside the host cell often requires 
rigid purification steps afterward and sometimes even a disassemble-reassemble step to 
guarantee a high quality product 26,119. A new in vitro cell-free processing approach 
circumvents the tedious build-break-rebuild paradigm and introduces a large-scale 
extracellular purification step of the building blocks first before assembling the final 
products in vitro 25. 
Some modifications of the VLPs have broadened their application. Multi-protein 






The final product of multi-antigenic VLPs provide protection to more than one pathogen 
132,133. On the other hand VLPs can also serve as a good delivery platform given their 
ideal size and surface feature. They can be chemically conjugated with other proteins or 
non-protein molecules to assist the immunopotentiation against them in an engineered 
manner 2,134–136. 
Unlike the other commonly used adjuvants like AH, AP and MF59, which mainly 
induces a humoral response, VLPs can initiate both humoral and cell mediated response 
114,137,138. More recently efforts have been made to further enhance the response to 
VLPs by anchoring stimulatory molecules like GM-CSF and IL-4 or targeting molecules 
like CD40L on their surface 139,140. 
VLPs are some of the first nanoengineered vaccines that have been 
commercialized. The first VLP vaccines reached the market as early as 1980s and were 
HBV vaccines (Engerix-B® from GSK and Recombivax HB® from Merck) 141,142. Aluminum 
adjuvants were formulated with these vaccines to achieve optimal response. More 
recently approved VLP vaccines include two HPV vaccines (Cervarix® from GSK and 
Gardasil® from Merck) 143. Cervarix® are made of self-assembled VLP from HPV type 16 
and 18 adjuvanted with AS04, while Gardasil® are made of HPV type 6, 11, 16 and 18 
adjuvanted with aluminum adjuvant 144–146. HPV type 16 and 18 along were responsible 
for about 70% of cervical cancer cases 147.  The vaccines have been proven to be highly 








Emulsions are another type of nanosized adjuvants commonly used in vaccines 26,148,149. 
They come mainly in the forms of oil-in-water and water-in-oil emulsions, and have a 
size between 50nm to 600nm 150. Emulsions can either contain antigens inside the oil 
particles or simply be administered along with the antigens 150. Here two emulsion 
adjuvants that already have been tested in human vaccines will be discussed.  
1.4.4.1 Montanide 
Montanide are similar in character to Incomplete Freund’s adjuvant (IFA), which is a 
water-in-oil emulsion made with mineral oil. However, the latter have been prohibited 
in human vaccines given the strong adverse effect it induces. The components of 
Montanide, on the other hand, are biodegradable and have reduced cytotoxicity 
compared with IFA 151. Right now there are several different types of Montanide 
available and two of them, ISA51 and ISA720, are being tested in human vaccines 111. 
Both types are biodegradable squalene-based water-in-oil emulsion with mannide 
monooleate as an emulsifier 152.  
Although the mechanism by which Montanide enhances the immune response is 
not known, a depot effect is believed to play some role 152. Similar to IFA, montanide 
induces both humoral and cell mediated immune responses 151,153,154. Given its strong 
immune boosting potential, montanide is being tested mainly in therapeutic vaccines 
and against those infectious diseases current adjuvants could not induce an effective 






clinical trials for HPV associated cancers and WHO grade 2 low-grade gliomas 155,156. ISA 
720 was tested in a vaccine against schistosomiasis, a prevailing helminth infection. The 
vaccine induced a balanced Th1/Th2 response, characterized with both antigen-specific 
IgG1 and IgG2c in the serum, and a drastic reduction of parasite burden was observed in 
a mouse model 157. Both ISA 51 and ISA 720 have also been used in malaria vaccines 
158,159. 
1.4.4.2 MF59 
MF59 is another widely administered vaccine adjuvant, second only to aluminum salts. 
It is an oil-in-water emulsion composed of biodegradable squalene and usually comes in 
a size around 160nm in diameter 160,161. MF59 is widely applied in influenza vaccines in 
Europe and haven been proven highly effective 162,163. One of the substantial benefits it 
brings to vaccines is the enhancement of immune response toward influenza vaccines in 
elderly people, making MF59 the first demonstration that a proper selection of 
adjuvants can help optimize protection in certain designated populations, especially 
those immunocompromised groups 12. Recently it was also found that MF59 significantly 
enhanced the magnitude of the adaptive response along with a early gene signature 
characteristic of a strong innate response to a trivalent inactivated influenza vaccine in a 
group of 14 to 24 month old children, further supporting its role as a wide-applicable 
vaccine adjuvant 164. 
Similar to aluminum adjuvants, the mechanisms of how MF59 enhances the 






adjuvants, MF59 does not retain antigens at the injection site so its adjuvanticity seems 
to lie more directly in its effect on the immune system 165. It can increase antigen uptake 
by APCs and promote their differentiation toward activated DCs 88,166. A detailed study 
of the injection site revealed that the resident macrophages and DCs can be activated by 
the administration of MF59 and release an array of proinflammatory cytokines and 
chemokines, which can then recruit more inflammatory cells including monocytes, 
granulocytes, macrophages, and DCs to the injection site and secret even more 
proinflammatory molecules. Thus, a positive amplification loop can be formed to create 
an ideal localized environment for APCs to be attracted and activated. Although MF59 
does not retain antigens, the rapidly recruited APCs can still pick up the leftover antigen 
there and travel to the draining LN to drive the adaptive immune response 83,167. The 
question is which MF59 induced danger signal is the trigger of such a reinforcing 
inflammatory response? One of the studies found that compared with AH and IFA, MF59 
led to a high concentration of ATP at the injection site and injection of apyrase, an ATP-
hydrolyzing enzyme, abrogated the cell recruitment 168. This suggests ATP released from 
stressed or damaged local cells may play a critical role in MF59 adjuvanticity.  
In the past two years, our knowledge about MF59 adjuvanticity expanded from 
the injection site to the draining LN. MF59 could persist in the subcapsular sinus and 
medullary region of the draining LN along with unprocessed antigens for at least two 
weeks. It also promotes the transfer of immune complex-trapped antigens to follicular 
DCs 169. In addition, MF59 could provoke a follicular T helper cell (Tfh) response, which 






month post immunization 170,171. Such an effect on Tfh and GC B cells could be observed 
in infant mice of only three weeks in age, again supporting the immunopotentiation 
effect of MF59 in certain targeted populations.  
Since its launch in human vaccines in 1997, MF59 has been exclusively used in 
influenza vaccines in clinics 14. The expansion of its application in other vaccines like 
those against herpes simplex virus, HBV, hepatitis C virus (HCV), and HIV are also 
currently under investigation 160. Replacing aluminum adjuvant with MF59 in the 
prevailing pediatric DTaP vaccine induced a more prompt onset of response and 
superior antibody quality, indicating a promising potential for MF59 in human vaccines 
172.  
1.4.5 Polysaccharide Nanoparticles 
In the search of potential novel adjuvant materials, polysaccharide polymers that are 
widely available in nature caught the eyes of vaccinologists. They have properties that 
are ideal for inclusion in vaccine formulations: polysaccharide usually have low toxicity; 
they are abundant in bacteria, fungi, and plants so can be easily manufactured at low 
cost; the morphology of many polysaccharides can be chemically modified to nanosized 
particles and often the surface can be functionalized which are ideal for vaccine delivery; 
immunostimulation has also been observed in several different polysaccharide polymers 
173. 
Pullulan is a α-1,4-;α-1,6-glucan that can be found in fungus Aureobasidium. A 
cholesteryl-containing pullulan formed nanoparticles 30nm in size and had 






direct activation of DCs and could result in a stimulation of both T and B cells 176. In 
addition to pullulan, another type of glucan, β-glucan has also been found to possess 
immunostimulatory property and has been tested for both prophylactic and therapeutic 
vaccines 177. It can be recognized as PAMPs by several lectin receptors of the innate 
immune system 178. 
Inulin is a water soluble fructose polymer purified from the plant chicory 179,180. 
Inulin particles are about 3 nm in size 181. The native form of inulin induces no 
immunological activity, but turns highly stimulatory when crystallized into larger 
particles, or so called AdvaxTM adjuvants 182. Inulin induces both humoral and cell-
mediated responses but its mechanism is not well understood. It may involve 
complement activation, assisting antigen processing, and recruitment of inflammatory 
cells 173,179. Inulin has been tested in vaccines against influenza, HBV, and cancer 179,183–
185. An inulin adjuvanted influenza vaccine just finished phase I clinical trial and 
demonstrated good results 186. 
Chitosan is a linear polysaccharide polymer composed of β-(1-4)-linked D-
glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit). 
Nanoparticles made from chitosan have good biocompatibility and can be modified into 
different sizes and shapes 187. Chitosan can directly activate maturation of DCs by 
inducing type I interferons. The induction of interferon production and the following DC 
maturation was found to require two intracellular DNA sensors: cGAS and STING, 
indicating the importance of the STING pathway in chitosan adjuvanticity 188,189. The 






mtDNA into cytoplasm induced by the uptake of Chitosan. Chitosan nanoparticles have 
been tested in DNA vaccines 190, and vaccines against Newcastle disease in poultry 191 
and HBV 192. In addition chitosan has also showed promises as a mucosal vaccine 
adjuvant. This is largely due to its special capability to adhere to the mucosal surface 
and disrupt the tight junctions between epithelial cells 193–195. This is found to be partly 
due to the positive charge of chitosan nanoparticles that enables it to adhere to and 
interact with the negatively charged mucosal epithelial cells. A chitosan formulated 
intranasal vaccines protected mice from Streptococcus pneumonia challenge 196. 
Last but not least, polysaccharide polymers can also form hydrogels, a crosslinked 
polymer network 175,197,198. This nanosized three dimensional structure can be tailored 
to different mesh sizes and have high flexibility for conjugation with antigens or other 
stimulatory molecules, indicating the potential as a vaccine adjuvant 197,199 
1.4.6 Liposome 
Liposomes are nanosized particles made up of biodegradable phospholipid membrane 
shell and they are usually between 100 nm to 400 nm in diameter 6,26,111,200. They can 
come as unilameller vesicles with a single phospholipid layer or multi-lamellar vesicles 
with more than one phospholipid layer 6. Antigens can be incorporated into liposomes 
through either inside the aqueous core, embedded in the phospholipid membrane, or 
simply absorbed on the liposome surface 201. Liposomes are mostly considered as 
vaccine delivery systems, however, the intended immune profile can be modified by 
changing electrostatic charges or integration of immunostimulatory molecules 202,203. A 






spontaneously assemble with polymer condensed DNA into a 150 nm size particle with 
DNA located inside. These nanoparticles were called liposome-polycation-DNA 
nanoparticles (LPDs) and have been tested for DNA vaccines 204,205. 
Since phospholipids used in preparation of liposomes are also found in 
mammalian cells, they have little adjuvanticity by themselves 111,206. Efforts have been 
made to modify the surface of liposomes to make it less inert. Cationic liposomes can 
activate the cell-mediated immune responses 207 and a PEG-mannose functionalized 
cationic liposome was found to be capable of targeting antigens to the draining LNs and 
promoting a long term immunological memory 208. 
Liposomes have been tested in different prophylactic vaccines, but due to its low 
immunogenicity there is no sole liposome adjuvanted vaccine 209,210. However, 
liposomes have been explored as a platform for second generation adjuvants like AS01 
by GSK, which is comprised of liposome, MPL, and QS-21 211. Liposomes have also been 
studied in therapeutic vaccine for cancers 55. Tecemotide is a liposome and MPL-based 
vaccine for non-small cell lung cancers and was found to elicit a potent cell mediated 
immune response against cancer cells in the primary studies 212. However, failure to 
meet the primary endpoint of improvement in patient survival in a phase III clinical trial 
led to discontinuation of its development in 2014.  
1.4.7 Virosome 
Virosomes are sometimes regarded as a type of liposomes. However, virosomes utilize 
the whole envelop of a virus as an adjuvant to incorporate antigens and activate the 






get for immunopotentiation, while liposome just happens to be one of the components 
14,111. Virosomes have high immunogenicity and can activate both humoral and cell-
mediated immune responses 213. The responses were potent and long lasting in all age 
groups 214. 
There are currently several virosome adjuvanted vaccines on the market, including 
influenza vaccines Inflexal® and Invivac® and HAV vaccine Epaxal® 214–217. There was also 
an intranasal virosome-based influenza vaccine NasalFlu® licensed in Europe, but this 
was later removed due to reported adverse effects 213. 
1.4.8 ISCOM 
Immunostimulating complex (ISCOM) is nanosized cage-like particles that were 
specifically developed in the 1980s to serve as an adjuvant in vaccines. It is made by 
combining cholesterol, phospholipid, saponin adjuvant (usually Quil A or QS-21 from the 
South American tree Quillaja saponaria), and antigens. A matrix will form which entraps 
the protein antigen inside, often through hydrophobic interaction 148,218–221. ISCOM 
particles are about 40nm in diameter. Another form of ISCOM is ISCOMATRIX, which is 
made of cholesterol, phospholipid, and saponin in a 1:1:6 ratios without the antigen. 
Antigen can be added to preformed ISCOMATRIX particles. This simplifies the 
formulation process of ISCOM and expands the list of antigens eligible for this novel 
adjuvant, since now antigens are no longer required to be trapped in through 







ISCOM works at least partially by its strong stimulatory effect on DCs. It can 
assist the antigen uptake by this professional APC and extend its retention in draining LN 
for driving the adaptive immune response 226. ISCOM also has a tendency to destabilize 
the endosomal membrane, leading to leakage of antigen into the cytoplasm to be 
ultimately presented on MHC I molecules 227. The destabilization of endosomes also 
activated the NLRP3 inflammasome similar to aluminum adjuvants. This leads to the 
production and secretion of IL-1β and IL-18 by DCs. Between the two, IL-18 was 
revealed to be indispensible for the innate and following cell mediated immune 
response 228.  
As a designated vaccine adjuvant, ISCOM has demonstrated excellent 
immunogenicity. The provoked immune responses are usually well-balanced, containing 
both humoral and cell mediated responses. 229,230. Moreover, ISCOM formulated 
influenza vaccines have been demonstrated to offer cross protection and support 
epitope spreading along with antibody affinity maturation 231,232. In addition, the cell-
mediated immune responses induced by ISCOM surpass any other adjuvants, which 
makes it the gold standard on this perspective 14. Such potent cellular response 
generation is also observed in nonhuman primates 233, and in clinical trials for cancer 
immunotherapy 234,235. 
ISCOM is immunogenic not only through injection, but through mucosal routes 
as well. Intranasally administered ISCOM induced both mucosal and systemic responses 
with high levels of IgG and IgA 236,237. ISCOM formulated vaccines delivered via oral and 






against the codelivered antigens, which demonstrates ISCOM as a promising mucosal 
adjuvant 238,239. The breakdown of tolerance was dependent on the presence of Quil A in 
ISCOM 239.  
ISCOM has been tested in prophylactic vaccines against influenza, herpes simplex 
virus, dengue virus 219,230,240. However, concerns over the safety of saponin (even though 
the less toxic Quil A or QS-21 is used in ISCOM) have deterred application of ISCOM in 
marketed vaccines. Although tolerance toward QS-21 is much better when it is buried 
inside ISCOM than in its bare form 241 and in spite of continuous efforts to further purify 
the saponins in ISCOM 242, more time would be needed before ISCOM can be accepted 
by major vaccine companies as a choice for their prophylactic vaccine products. For the 
moment the focus of ISCOM is on its application in immunotherapy, especially toward 
cancer treatment 234,235,243. 
1.4.9 Proteosome 
Proteosomes are nanoparticles made from the outer membrane proteins of the Gram-
negative bacteria Neisseria meningitidis, which was first applied in a vaccine against the 
very same pathogen in 1980s 111. Proteosomes are hydrophobic in nature, limiting their 
application to apolar and amphiphilic antigens 111. Proteosomes have been 
demonstrated to be an effective intranasal adjuvant. They elicited strong antigen 
specific IgA and could protect mice from post immunization challenges with various 
pathogen models 244–246.  
Proteosomes were tested in vaccines against a diverse background of pathogens 






respiratory syncytial virus 245.However, interest in this specific vaccine delivery system 
slowly dwindled during the past ten years and there have been few reports on 
formulating vaccines with proteosomes in recent years.  
1.4.10 Other inorganic nanoparticles 
In addition to aluminum salts, other inorganic nanosized materials have been tested for 
coformulation with vaccines. They are not the main stream of adjuvants right now, 
mainly due to concerns over their degradability and overlap of property and stimulatory 
effect with the dominant aluminum salts, making the study of them somewhat 
redundant.  
1.4.10.1 Gold nanoparticles 
Gold nanoparticles in the size range of 2 to 200 nm have been applied as a vaccine 
delivery system 6,111. The biggest advantage of gold nanoparticles is that they can be 
easily fabricated into different sizes and shapes to meet the tailored needs 253. The 
surface of gold nanoparticles can be readily modified with carbohydrate to build 
carbohydrate systems with defined geometries 254,255. The surface of gold nanoparticles 
can also be functionalized with chitosan to enhance their immunostimulatory effect 256. 
The high density of gold nanoparticles make them a good platform for administering 
DNA vaccine, and they were shown to deliver DNA cargo directly into cells 257. When a 
HBV DNA vaccine was delivered with gold particles intradermally into mice, combined 
with electroporation, a robust immune response was observed 258. However, such a 






Gold nanoparticles have been tested for vaccines against respiratory syncytial 
virus 260, influenza 261, foot-and-mouth disease 262, HIV 263, as well as therapeutic 
vaccines against cancer 264. 
1.4.10.2 Silica nanoparticles 
Silica nanoparticles have good biocompatibility and can be modified as different porous 
spheres for the delivery of antigens 26. One of these spheres, mesoporous silica 
nanoparticles (MSN) can be prepared with organic template methods to yield 
standardized platforms to pair with antigens of different molecular weights and surface 
properties 265. 
MSNs are between 50 nm to 200 nm in size. They have a high antigen loading 
capacity with a large surface area and can release their cargo in a controlled manner 
with their tunable mesoporous structure 266–269. Incorporation of antigen into MSNs 
could also enhance its stability against nonideal conditions 270. Relevant studies 
demonstrated MSNs to be readily degradable in the biological systems, suggesting them 
to be suitable for clinical use 271–273. The surface of MSNs can also be functionalized with 
different molecules to achieve specific purposes like precise cell recognition, increased 
cellular uptake, and shielding cargo from cleavage 274–276. 
Silica nanoparticles have been tested in vaccines against HBV 277 and bovine viral 






1.4.10.3 Calcium phosphate nanoparticles 
Calcium phosphate can be produced as 50 – 100 nm particles by mixing calcium chloride, 
sodium citrate, and dibasic sodium phosphate in controlled conditions 281282. Calcium 
phosphate nanoparticles induced a long-lasting cell mediated immune response in 
mouse models 283, while functionalization of the particles with stimulatory molecules 
like flagellin enhanced the immunopotentiating effect of these molecules, possible by 
rendering them in a particulate form 284. Incorporation of antigens on the surface of 
calcium phosphate also led to the cross-linking and activation of B cells 285. These results 
indicate that this nanoparticle can activate the immune system through multiple 
pathways.  
Calcium phosphate nanoparticles have been tested in Newcastle disease vaccine 
286 and DNA vaccine 282. They have also been tested in mucosal vaccines 287. 
1.5 Interactions between nanoparticles and antigens 
For vaccine formulation, nanoparticles are usually expected to be associated with 
antigens. This means antigens can either be encapsulated inside the particles or they 
can be merely associated on the surface of nanoparticles 6. For some nanoparticles with 
hydrophobic components like liposome, apolar antigens can also be buried in its lipid 
bilayer 200,201. For surface association, depending on the desired strength, antigens can 
also be simply absorbed or chemically conjugated onto the nanoparticles 26. 
To encapsulate antigens, they need to be added to the nanoparticle components 
during the production process26. Encapsulation offers a way for the adjuvants to protect 






controlled manner to a targeted location of the body or a specific compartment inside 
the cell.  Current manufacturing protocol can not guarantee encapsulation of all the 
antigens during the process. For example, the antigen encapsulation rate for liposomes 
is between 25% to 72%, depending on the type of antigen and the synthesis process 288–
290. Although this method protects the cargo, there are several drawbacks. First, the 
involvement of antigens during the production of nanoparticles requires an aseptic 
environment for the manufacturing process. This considerably increases the cost of 
production. Second, the loading rate of the nanosized adjuvants, which means the 
weight ratio of encapsulated antigen to the whole carrier system, is still low. Currently 
this number stays around 5% for most nanoparticles 28. To meet the desired dosage of 
antigen, an excess amount of carrier material would often have to be administered, 
which may bring toxicity or other side effects. Third, the particle break-down and 
antigen release are difficult to be tailored. For example, injected PLGA nanoparticles 
often release their cargo too rapidly (so called “burst release”), considerably decreasing 
the amount of antigens available to interact with the immune cells 40. 
The two main forces contribute to antigen absorption on nanoparticles are 
hydrophobic interaction and electrostatic attraction 26. The first one play a role in 
particles with a hydrophobic surface such as certain emulsions 17. Electrostatic 
attraction works when the adjuvants and antigens are oppositely charged. This is an 
important consideration for the selection of adjuvants during formulation. For example, 
for the two types of aluminum salts, AH has a positive surface charge so attract those 






positively charged antigens 22. Besides adjuvant and antigen, some external conditions 
like the pH, ionic strength, and excipient affect electrostatic antigen absorption 291–293. 
Hydrophobic interaction and electrostatic attraction are relatively weak forces. Upon 
administration into the body, the change in conditions may lead to rapid elution of 
antigens from the adjuvant. This was clearly demonstrated in experiments in which 
electrostatically absorbed antigens quickly released from aluminum salt upon exposure 
to sheep interstitial fluid 70,294,295. This suggests that antigens may no longer be 
associated with the adjuvants when they encounter immune cells following injection.   
Antigen conjugation refers to chemically crosslinking to adjuvants 296,297. This is a 
much stronger association force than adsorption and leads to the uptake of the antigen 
along with adjuvant by immune cells. In the case of aluminum salts, ligand exchange is a 
form of conjugation between antigen and AH. It is equivalent to a covalent bond and 
antigen bound to AH under this mechanism is resistant to release upon exposure to 
sheep interstitial fluid 70. However, to be bound to AH by ligand exchange, an antigen 
needs to contain phosphate groups, limiting the application of this mechanism. In recent 
years, different chemical methods, like the new “click” chemistry, have been developed 
to conjugate a broad spectrum of antigens and nanoparticles in a straightforward and 
controllable manner 298. Through binding to the surface of nanoparticles, antigens are 
presented to immune cells in a similar way as they are on the pathogen, and more likely 
to induce a similar immune reaction 6. 
Although antigen association with nanoparticles may enhance delivery, it can 






adjuvants are sometimes less stable than those in solution and more prone to chemical 
degradation 292,300,301. One should therefore consider if antigens and adjuvants can be 
merely mixed without any form of association before administration. Results from some 
of these attempts, including the most commonly used aluminum adjuvant and MF59, 
show that non-associated antigens can elicit a strong immune response 302,303. This is 
likely due to the immunopotentiation capacity of these nanoparticles to recruit and 
activate immune cells to the site of injection. Indeed, more and more nanoparticles are 
being discovered to activate immune cells even in the absence of antigens, supporting 
future formulations of simply mixing adjuvants and antigens 253,304,305. 
Antigens and adjuvants interact with different mechanisms and strengths with 
various results. Optimization requires a case by case evaluation for each vaccine. It is 
important to view the antigen and adjuvant as an integral part of the vaccine 
formulation instead of separate entities. 
1.6 Relation of nanoparticles with APCs 
Nanoparticles excel among other candidates to be the platform for the next generation 
adjuvants partly due to their efficiency in cellular uptake and APC activation. In this case, 
it is vital to understand the interactions between nanoparticles and APCs, especially the 
DCs which connect the innate and adaptive immune responses 306–309.  
Many factors including the size, charge, shape, and hydrophobicity of the 
nanoparticles affect their uptake by APCs 3,26. Usually particles similar in size to the 
pathogens are more readily taken up by APCs presumably due to evolutionarily selected 






particles of 300nm in diameter demonstrated superior internalization compared with 
those with a diameter of 1, 7, or 17 μm 311. The optimum size for uptake also depends 
on the material of the particles and the type of cells 312. It was found that DCs are more 
efficient at internalizing particles in the size of 20 n to 200 nm while macrophages prefer 
those between 500 nm to 5 µm 310. Positively charged nanoparticles are overall more 
easily taken up by APCs than negatively charged or neutral particles 313,314. This can be 
partly explained by the fact that the cell membrane is negative charged so cationic 
nanoparticles have an tendency to be attracted to the cells 313. Shape also affects the 
level of particle uptake. In some situations it may also impact the mechanism of 
internalization 315. In general, shape plays a larger role in bigger particles. For particles 
with sizes comparable to immune cells, rod-shaped particles are poorly taken up by 
APCs, possibly due to the inhibitory effect of the low curvature geometry alongside the 
rod 316. Nanoparticles with a hydrophobic surface more easily activate the complement 
cascade on their surface and the subsequent opsonization of the particles would 
facilitate their internalization by APCs 317,318. In addition to the above mentioned 
features, adjuvants can also be functionalized with a different targeting ligand to adjust 
their level of uptake or even direct them to a specific type of APCs 3,26. 
APCs can internalize nanoparticles through various mechanisms. The most 
commonly known one is phagocytosis, which is an actin-based mechanism mainly used 
by APCs and other phagocytes 6. In addition to phagocytosis there are several 
endocytosis mechanisms that can contribute to the internalization of adjuvants 






macropinocytosis, and clathrin- and caveolae-independent endocytosis 4,317,319. Clathrin-
mediated endocytosis is associated with the formation of a clathrin lattice that forms a 
net-like basket around the newly formed endosome. It is a regular way of cells to 
internalize particles smaller than 150 nm in size. Caveolae-mediated endocytosis occurs 
when the vesicles are coated with caveolin dimers. It is depend on a GTPase called 
dynamin and is involved in internalization of some particles between 50 nm to 80 nm in 
diameter. Macropinocysis is the active engulfment of extracellular particles and milieu 
starting with the ruffling of surface membrane. It has low selectivity but is capable of 
internalizing particles larger in size, usually around 500 nm to 5 µm 4. Some other non-
clathrin and non-caveolae endocytosis mechanisms were also discovered. They were 
found to be associated with uptake of smaller nanoparticles around 20 nm in diameter 
320. 
One thing to point out is after administration of nanoparticles into the body, 
biomolecules( including proteins, lipids, etc) in the interstitial fluid and serum may 
quickly adsorb onto the surface of the particles. This would lead to the formation of a 
corona outside the nanoparticles. Such a layer of biomolecules will actually be what 
APCs “see” of the surface of the nanoparticles and subsequently influence their 
interaction with the cells, instead of the original surface of nanoparticles 298. In this case, 
cautions should be taken when predicting the interaction of nanosized adjuvants with 
APCs in vivo. 
After internalization, nanoparticle containing endosomes will gradually mature 






this process, the antigen cargos will be degraded by the proteolytic enzymes into 
peptides and then loaded onto MHC class II molecule in late endosome, which will 
subsequently transport to the cell membrane and present the loaded antigen to the 
corresponding CD4 T helper cells. Those cells can then drive the production of antigen-
specific antibodies by B cells 6. However, nanoparticles sometimes functions as more 
than just a cargo carrier inside APCs. For example, ISCOM was found to have a tendency 
to undermine the endosomal membrane, which can leak the antigen into cytoplasm. 
There the antigen can be processed by proteasome into peptides and the peptides will 
then be transported to endoplasmic reticulum (ER) by transporter associated with 
antigen presentation (TAP) to load onto MHC I molecules. Loaded MHC I can then travel 
to the cell membrane to drive antigen-specific CD8+ T cell response 227. On the other 
hand aluminum adjuvant and ISCOM were both found to destabilize the lysosome and 
the escape of lysosomal content consequently led to the assembly an intracellular 
machinery of NLRP3 inflammasome, which was responsible for the production and 
secretion potent proinflammatory cytokines IL-1β and IL-18 93,228. Such an escape of 
lysosomal content may also lead to MHC I presentation. These results indicate that once 
inside APCs, nanoparticle adjuvants can still impact antigen processing and cell 
activation. Major effects of nanoparticle adjuvants on APCs are summarized and 
depicted in Figure 1.1.  
1.7 Nanoparticles induced inflammation 
In an infection, innate cells recognize the presence of pathogens through a limited 






adaptive response, they form a integral part of defense system of the host to protect 
from infections 13,14. There is a growing appreciation of the engagement of nanoparticles 
with the innate cells, especially the inflammatory response induced at the injection site. 
Even for aluminum adjuvants, which were long believed to work through a depot effect, 
it is now clear that the inflammatory response plays a critical role in 
immunopotentiation 321,322. The major benefit of such an inflammatory response is that 
it can attract APCs to the vicinity of the vaccines, where they can pick up antigens and 
be activated by the local inflammatory environment, an effect that has been called 
“reverse targeting ”14. The activated antigen-containing APCs can then travel to the 
draining LN to drive the adaptive immune response. Recent evidence supporting the 
vital role of inflammatory response came in a study investigating a MF59 adjuvanted 
influenza vaccine in a group of 14 to 24 months old healthy children. It was found that 
the transcriptional signatures  of antiviral IFN genes and genes involved in APC 
responses on Day 1 directly correlated with the level of detected hemagglutination titer 
four weeks later 164. This indicates the quality of the induced inflammatory response at 
the injection site can directly impact the success of the vaccine.   
The inflammatory response to aluminum adjuvants has been well characterized.  
For aluminum adjuvants, the response is characterized by an early influx of neutrophils 
during the first two days followed by other inflammatory cells like monocytes, 
macrophages, DCs, and eosinophils. The inflammatory response was detected for at 
least seven days 83–86. For MF59, a similar kinetic of inflammatory response was found 






after immunization and was resolved by Day 21. However, comparing with aluminum 
adjuvants, MF59 induced a strong inflammation characterized by a considerably large 
number of inflammatory cells 83. A comparison of the molecular signatures between 
these two adjuvants revealed that while aluminum adjuvant regulated 312 genes, MF59 
changed the expression of 819 genes 167, matching its superior effect on cellular 
recruitment.  The perturbation of gene expression by MF59 lasts for about seven days, 
also correlating to the cellular kinetics at the injection site 164. These data suggest a 
programmed sequence of events following administration of vaccines. First, resident 
macrophages, DCs and tissue cells are activated by the adjuvant and react by secreting 
an array of proinflammatory cytokines and chemokines which attract monocytes, 
granulocytes, and more APCs to the injection site. The newly recruited inflammatory 
cells are also activated upon contact with the adjuvants and secrete even more 
proinflammatory molecules, thus building an positive feedback loop that in the end 
leads to a strong inflammatory response 14. During this process, the initial gene 
signature determines the level of innate response and ultimately the quality of the 
adaptive protection.  
Given the essential role inflammation play in a successful adjuvant, one thing to 
point out is that, although a strong inflammatory response is beneficial for immune 
protection, a long lasting inflammatory at the injection site is also not desirable and may 
raise concerns of the recipients. In this case, the ideal inflammatory response provoked 






1.8 Nanoparticles in draining LN 
Although the inflammatory response occurs at the injection site, the adaptive immune 
response develops in the draining LN, where naïve B and T cells circulate 3. 
Nanoparticles can arrive at the draining LN through two ways, which to some extent 
depends on the size of the nanoparticles 323,324. Nanoparticles may flow through the 
lymph system to the LN and be taken up by the lymphoid tissue resident DCs, which can 
then process the cargo and drive the adaptive response in the same lymphoid organ 
325,326. This usually happens only to nanoparticles smaller than 100 nm 327–329.  
Alternatively, nanoparticles can be taken up by local or recruited APCs at the injection 
site and be passively transported to the LN 3,330. This is the transport method for 
particles larger than 200nm, since particle-containing migratory APCs can squeeze 
through the tight junctions between endothelial cells to reach the LN 30,326,329. In 
addition to size, other factors like route of administration, charge, and surface 
functionalization may also affect the drainage of nanoparticles to the LN 26. In addition 
to localizing in migratory or resident APCs, nanoparticles can be present in other cells in 
the draining LN. A recent study reported that MF59 is retained in the subcapsular sinus 
and medullary macrophage compartment of the LN for at least two weeks after 
intramuscular administration. During a secondary immunization, the retained MF59 was 
found to hold unprocessed antigens. Later these antigens were translocated from the 
macrophage area to follicular DCs 169.  This indicates nanosized adjuvants may enhance 






In the draining LN, antigen-containing and adjuvant-influenced APCs will present 
the processed antigen peptide to a specific group of T cells called T follicular helper (Tfh) 
cells. Tfh cells are a specific CD4 T cell subpopulation characterized phenotypically by 
the expression of CXCR5 and PD1. Their main role is to guide the activation of antigen-
specific B cells and facilitate the forming of GC, where B cells can go through isotype 
switch and affinity maturation to produce high quality antibodies against intended 
pathogens 331–333. This suggests Tfh and GC can also be involved in the mechanism of 
nanoparticle adjuvants. Indeed, recently it was reported that MF59 promotes Tfh cells 
response in an influenza vaccine, which can be observed even in infant mice of three 
weeks old, although the authors did not investigate further to determine whether this 
was due to a direct effect of MF59 on Tfh cells or indirectly through MF59 activated 
APCs 171. Moreover, through Tfh MF59 also significantly enhanced the GC B cell 
differentiation and persistence 170. These results indicate draining LN is another location 
vaccinologists need to focus on in order to fully understand nanoparticle adjuvanticity.  
1.9 Clearance of nanoparticles from body 
In addition to its immunopotentiation capacity, application of nanosized adjuvants in 
vaccines also needs to consider their clearance from the body before they can be used 
in people. For example, a pharmacokinetics study tracing maximum dosages of AH or AP 
allowed in human vaccines (0.85mg) in New Zealand White rabbits revealed  that 17% of 
AH and 51% of AP entered blood circulation and were subsequently excreted through 
urination over a period of 28 days 334. Based on this and other similar studies, the 






aluminum adjuvanted pediatric vaccines was calculated and it was found to be well 
below the risk level established by Agency for Toxic Substances and Disease Registry, 
demonstrating that aluminum adjuvants are generally safe 335.  
Clearance of injected nanoparticle vaccines can be achieved through either 
immune cell digestion or renal and biliary excretion. For biocompatible nanoparticles, 
they can be degraded by immune cells like macrophages, DCs, and granulocytes. These 
cells internalize the nanoparticles and the vesicles gradually mature into 
phagolysosomes, which has an acidic pH along with other digestive enzymes to digest 
the intracellular particles 336. Nondegradable nanosized adjuvants need to be excreted. 
The kidneys filter blood through glomerular capillaries.  The filtration mechanism 
involves a group of highly differentiated cells named podocytes which form filtration 
slits with a size of 4-6 nm 337. Nanoparticles smaller than 6nm will be able to pass 
through into the urine while the larger ones will be retained 338,339. However, factors 
other than size also play a role in renal excretion like surface charge and particle shape. 
In general, negatively charged particles pass the glomerular filtration more easily than 
positively charged particles, possibly because the negatively charged podocyte cell 
surface retains the positively charged particles 340,341. On the other hand, nanotubes 
with a length between 200 nm to 300 nm and a molecular weight of  350 kDa to 500 kDa, 
that is ten time of the maximal weight of nanospheres allowed to be pass through the 
filtration slits, were observed in the urine 342.  Mathematical modeling revealed this 
might be due to a preferred orientation of the tube in the blood flow while passing 






In liver, blood flows through a permeable capillary network called sinusoids to reach 
the central vein 336. These permeable capillaries have a fenestrated epithelium that 
allow any particle smaller than 150 nm to pass freely into an area called the 
perisinusoidal space 343. The perisinusoidal space is surrounded by hepatocytes. They 
can take up the particles through either macropinocytosis or receptor-mediated 
endocytosis and pass them to the other side of the cell into bile canaliculi for excretion 
within bile 344. Similar to renal excretion, nanoparticles excreted from the body through 
this route is also affected by factors other than size like the surface charge. Positively 
charged particles pass more easily through than negatively charged particles 345,346. This 
is probably because positively charged particles are more easily taken up by hepatocytes 
due to the electrostatic attraction between the particles and negatively charged cell 
membrane. One thing to point out is, depending on the nature of the nanoparticle 
material, there may be other clearance routes available other than renal and biliary 
excretion. For example, it was found aluminum can be excreted from sweating at a rate 
of between 234 µg to 7192 µg every day 347. Although most of the excreted aluminum 
here was in the form of elemental aluminum, this still provide a potential alternative 
clearance route for administered aluminum adjuvants.  
1.10 Closure 
With the vast development of nanotechnology in the past few decades, there are more 
nanosized adjuvants than ever in the candidate pool for the vaccinologists to choose 
from for the formulation their vaccines. The preferable size and the leniency to be 






generation adjuvants. However, what we know and have now may well just be the tip of 
the iceberg. There are more issues to be solved before the full potential of nanosized 
adjuvants can be achieved. They include but are not limited to: difficulties in scaling up 
the manufacturing of some adjuvants with good reproductivity, lack of fundamental 
understanding of their immunopotentiation mechanisms, and based on that to come up 
with more means to modify the nanoparticles for optimized immune responses. The 
answer to these questions will pave the road for the next generation of biodegradable 
nanosized adjuvants that can be easily synthesized with inexpensive component while 
are at the same time compatible with different antigens and other immune potentiators 
to induce a  strong and balanced immune response without conceivable reverse effects 
348. With that the prevention and treatment of some currently hard-to-control and 







Table 2.1 Characteristics of major nanoparticle adjuvants. 
          
Particle Size Surface charge Biodegradable References 
PLGA 100-1000 nm Negative  Yes 43,45 
Virus-like particles 20-800 nm Negative  Yes 112,113,115 
MF59 160 nm Negative  Yes 14,160 
Chitosan 50-500 nm Positive Yes 187,193 
Liposome 100-400 nm Negative  Yes 200,201 
ISCOM 40 nm Negative  Yes 221,222 















CHAPTER 2. DENDRIMER-LIKE ALPHA-D-GLUCAN NANOPARTICLES ACTIVATE 
DENDRITIC CELLS AND ARE EFFECTIVE VACCINE ADJUVANTS  
2.1 Introduction 
Vaccines are increasingly formulated with antigens consisting of subunits of microbial 
pathogens generated through chemical processing or genetic engineering to enhance 
their safety.  Unfortunately, these highly purified vaccine antigens are poorly 
immunogenic and adjuvants are 6 added to stimulate an effective immune response 12,14. 
Adjuvants work, at least in part, by increasing antigen uptake and by promoting the 
activation of DCs, a critical step in the initiation of the immune response. The most 
widely used adjuvants in human and veterinary vaccines are aluminum-containing 
adjuvants which generally induce a good antibody response, have an excellent long term 
safety profile, and are relatively inexpensive 22,349. However, aluminum adjuvants are 
ineffective in inducing a cell-mediated immune response; are inactivated by freezing; 
can have a detrimental effect on the stability of vaccine antigens; and are associated 
with local adverse vaccine reactions. In addition, aluminum is not biodegradable, and 
most of it is excreted via the kidneys and sweat glands 347,350. A variety of materials has 
been tested as vaccine adjuvants with variable degrees of success, and only a few 
alternatives to aluminum adjuvants have found their way into licensed vaccines 25. New 






response, but the single most important consideration is safety 348. In addition, 
adjuvants need to be compatible with various antigens, and inexpensive 348. 
 Over the past 20 years there has been increasing interest in the use of 
nanoparticles as vaccine adjuvants 6,26. Immunostimulatory effects have been reported 
for nanoparticles with a variety of materials, sizes, and surface properties. The physical 
and chemical composition of nanoparticles affects the type of cells that take up the 
particles, the trafficking within the cell and the degree and mechanism of 
immunostimulation 26,351. Here, we report on the immunostimulatory properties of 
positively charged phytoglycogen (PG) nanoparticles derived from the kernel of a 
genetic variant of sweet corn, sugary-1. The lack of a debranching enzyme in this variety 
of sweet corn results in the formation of dense highly branched, dendrimer-like PG 
nanoparticles that replace starch granules 352,353. The surface of PG particles can be 
chemically modified allowing for functionalization of the particles, such as generating 
amphiphilic nanoparticles with negative or positive charges. In this study, we 
investigated the effect of positively charged, amphophilic PG nanoparticles, termed 
Nano-11, on antigen uptake by DCs and activation of DCs in vitro and the adjuvant effect 
in vaccine formulations in vivo. 
2.2 Materials and methods 
2.2.1 Preparation of Nano-11  
The general reaction to prepare Nano-11 is depicted in Fig. 2.1. PG was reacted with 
octenyl succinic anhydride (OSA) to prepare phytoglycogen octenyl succinate (PG-OS), 






chloride (CHPTAC). Octenyl succinate (OS) groups confer hydrophobicity and negative 
charges, whereas the quaternary ammonium groups provide positive charges. The final 
product (PG-OS- CHPTAC) was positively charged by grafting excess amount of CHPTAC 
groups in comparison with OS groups. 
 Sweet corn kernels were used as the starting material for PG extraction. The 
kernels were ground and mixed with six weights of deionized water. The suspension was 
homogenized and centrifuged at 8000 g for 20 min. The supernatant was passed 
through a 270-mesh sieve. Three volumes of ethanol were added to the supernatant to 
precipitate polysaccharides. After centrifugation and decanting, the precipitate was 
suspended using ethanol and filtrated to dehydrate for three cycles. The solid material 
obtained after removing the residual ethanol was PG 354.  
 To the dispersion (20%) of PG (20 g of PG in 100 mL water), 1.8 g of OSA were 
gradually added in   h. The p  was maintained between  .5 and  .0 using 5  Na  . The 
reac on was carried out at  0   C and terminated after 24 h by reducing the pH to 6.0 - 
7.0 using 10% HCl. To the dispersion, 3 volumes of ethanol were added, and the 
precipitate was collected and subjected to 3 cycles of dispersion-filtration using ethanol. 
The solids obtained were placed in a fume hood to remove residual ethanol. The dry 
material collected is PG-OS.  
 The PG-OS material was ground to pass 80-mesh sieve, and 10 g of PG-OS was 
dispersed in 50 mL deionized water to form 20% dispersion. To this dispersion, 10 mL of 
CHPTAC was added over a period of 2 h while maintaining pH 11 using 5 M NaOH. The 






was adjusted to 6.0 - 7.0 using 10% HCl to terminate the reaction. The mixture was 
precipitated by adding 3 volumes of ethanol and followed by a three-time dispersion-
filtration washing procedure using ethanol. The collected solid was placed in a fume 
hood to remove residual ethanol. The dry material collected is PG-OS-CHPTAC (Nano-11). 
2.2.2 Transmission electron microscopy (TEM)  
Droplets of around 0.01% (w/v) PG-OS-CHPTAC in 0.02 M NaAc buffer (pH 5.5) were 
dried on a 400 mesh carbon-coated grid and stained by 2% aqueous uranyl acetate. 
Samples were imaged using a Philips CM-100 transmission electron microscope and 
collected with a CCD camera. 
2.2.3 Zeta potential and particle size  
Particle size and Z-potential of nano-11 at pH 2-11 were measured by dynamic light 
scattering (DLS) using a Zeta-sizer coupled with an MPT-2 titrator (Malvern). Dispersions 
of Nano-11 were prepared at 1.0 mg/mL and centrifuged at 5000 × g for 10 min. The 
supernatant was placed in the titrator with constant stirring and automatic titration 
using 1.0 M HCl as acid, and 0.5 M and 1.0 M NaOH as base. For each of 4 Nano-11 
solution samples, 3 readings of Z-average hydrodynamic diameter and zeta-potential 
were carried out at about a 0.5 interval between pH 2- 11. 
2.2.4 Generation of bone marrow derived dendritic cells (BMDCs)   
Dendritic cells were generated from bone marrow of BALB/c mice as previously 
described 355. Analysis by flow cytometry demonstrated that more than 90% of the 






2.2.5 In vitro cytotoxicity assay 
BMDCs were resuspended in RPMI-1640 supplemented with 5% fetal bovine serum (FBS) 
at a concentration of 106 cells/mL in a 24-well plate with 1 mL per well. Nano-11 was 
added at indicated concentrations and the plates were incubated at 37   C with 5% CO2 
for 2 days. Cell lysis was assessed by a lactate dehydrogenase (LDH) assay kit (Thermo 
Fisher Scientific, Waltham, MA). The % lysis was determined as the LDH concentration in 
the sample minus the LDH concentration in cells treated with medium only, divided by 
the concentration of LDH in cells treated with lysis buffer. 
2.2.6 Adsorption of proteins to Nano-11 
Proteins and Nano-11 were mixed in 10 mM 3-(N-morpholino)propanesulfonic acid 
(MOPS) buffer (pH 7.4) to reach a final concentration for Nano-11 at 1 mg/mL and 
protein as indicated. The suspensions with a volume of 1 mL were mixed by end-to-end 
rotation in 2 mL microcentrifuge tubes at room temperature ( 0- 5   C) for 1 h. The 
samples were then centrifuged at 14,000 g for 5 min and supernatants were harvested. 
Protein concentration in the supernatant was analyzed by the bicinchoninic acid (BCA) 
assay (Thermo Fisher Scientific). The amount of protein absorbed onto Nano-11 was 
determined by subtracting the amount in the supernatant from the total amount added 
initially. 
2.2.7 Labeling of proteins and Nano-11 
For labeling of antigens, 8 mg of protein was dissolved in 2 mL of double distilled water 
(dd H2 ) and transferred into carbonate bu er (p   .5) by overnight dialysis at     C 






made during the transfer. After dialysis, the protein concentration in the buffer was 
measured by the BCA assay. Fluorescein isothiocyanate (FITC) (Invitrogen, Eugene, OR), 
dissolved in anhydrous dimethylsulfoxide (DMSO), was added to antigen at the ratio of 
10 μg per mg of protein and mixed at room temperature for 1 hour. After the reaction, 
unbound FITC was removed through dialysis with storage buffer (10 mM Tris, 150 mM 
NaCl, and 0.1% NaN3 overnight at     C. Fluorescence labeling of Nano-11 was performed 
by 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDAC) crosslinking 356. Carboxylic 
end groups of Nano- 11 were activated by acidification using HCl 354. Acidified Nano-11 
powder (1 mg) was dissolved in 50 μL of  -(N-morpholino)ethanesulfonic acid (MES) 
buffer (50 mM, pH 5.0). One mg Alexa Fluor 647 hydrazide dye (Invitrogen) was 
dissolved in 1 ml of MES buffer. An aliquot of 180 µL from the vial was added to the 
dissolved Nano-11, the amount of dye was in a concentration sufficient to provide one-
fold of molar excess to the amount of Nano-11. To the previous mixture, EDAC 
(Invitrogen) was added at the ratio of 1 mg per mg of Nano-11 and mixed immediately. 
After 4 h at room temperature, excess of reactive sites of dye were blocked by adding 
MES containing 100 mM of trizma base. The mixture was centrifuged using a centrifugal 
ultrafiltration tube (Nanosep MT 300K, Pall, Port Washington, NY) at 12,000 g for 10 
minutes. The unreacted Alexa Fluor 647 was removed through dialysis to MES storage 
buffer.  
2.2.8 Antigen uptake  
For immunofluorescence of antigen/Nano-11 uptake, BMDCs were incubated in a 8 well 






RPMI supplemented with 5% FBS. FITC-labeled antigens, AF647-labeled Nano-11 or a 
premixed combination of both were added to reach a final concentration of 25 µg/mL 
for antigens and 250 µg/mL for Nano-11. After 2 h incubation, vessels were washed 
three times with ice cold PBS and cells were fixed with cold 4% paraformaldehyde for 5 
min before immuno uorescence staining with AF5  -labeled phalloidin. Slides were 
coverslipped with Prolong  old an fading with DAPI (Invitrogen), sealed and stored at 
    C. Confocal images were captured with a Nikon A1R MP microscope with a 60X 
objective. In some experiments, cells were incubated for 1 hour with 2 µM cytochalasin 
D (Sigma, St. Louis, MO) before adding Nano-11 and OVA.  
For FACS analysis of antigen uptake, BMDCs were incubated in 6 well plates and 
after the final wash cells were released from the plate by treatment with 1 mL 0.25% 
trypsin/2.21mM EDTA containing HBSS (Corning Cellgro, Corning, NY) for flow cytometry. 
2.2.9 Cytokine secretion by BMDCs 
BMDCs were cultured in 24-well plates at a concentration of 106 cells/mL. Where 
indicated, cells were primed with 100ng/mL lipopolysaccharide (LPS; Sigma) for 1 h. 
Nano-11 or aluminum hydroxide adjuvant (AH; General Chemical, Berkeley Heights, NJ) 
(50 µg/mL) were added and plates were incubated for two days before supernatants 
were harvested and stored at     C. Concentrations of cytokines were measured using 
ELISA kits (eBioscience, San Diego, CA). The effect of different inhibitors on cytokine 
secretion was tested in 96-well plates and inhibitors were added 1 h prior to LPS priming.  






plates is higher than that of cells cultured in 24-well plates. The final concentrations of 
inhibitors used were: 2.5 mM CA-074 Me (Calbiochem, San Diego, CA), 25 µM 
bafilomycin A1 (Sigma), 5 mM YVAD (Calbiochem). 
2.2.10 Flow cytometry 
Cells were washed with 2mM EDTA containing PBS, blocked with 1% normal rabbit 
serum containing PBS, and labeled with biotinylated-anti-mouse CD11c, PE-anti-mouse 
CD40, PE- anti-mouse CD80, or PE-anti-mouse CD86 (eBioscience). Cells were washed 
once more and stained with APC-Streptavidin (Jackson ImmunoResearch, West Grove, 
PA). After the final wash, cells were suspended in 2% paraformaldehyde. Cells were 
examined in a Canto II flow cytometer (BD Biosciences, San Jose, CA), and data were 
analyzed by FlowJo software (Flowjo, Eugene, OR). 
2.2.11 Immunoblots 
Cells were incubated in 6-well plates. After LPS priming and Nano-11 stimulation, 
supernatant was harvested and cells were lysed with 0.5 mL lysis buffer for 20 min on 
ice. Immunoblots were performed with 4-12% Bis-Tris Gels (Invitrogen), nitrocellulose 
membranes, goat anti- mouse IL-1β (R&D Systems, Minneapolis, MN), and peroxidase 
conjugated donkey anti-goat IgG (Santa Cruz Biotechnology, Santa Cruz, CA). Blot 
images were obtained with a G:BOX Chemi system (Syngene, Frederick, MD). 
2.2.12 Immunization 
Six week old female BALB/c mice were purchased from Harlan, Inc. (Indianapolis, IN) 
and housed with free access to food and water. All procedures were approved by the 






muscles with 50 µL of a formulation containing 200 µg/mL OVA (Invivogen, San Diego, 
CA) or 20 µg/mL anthrax recombinant protective antigen (rPA) (List Biological 
Laboratories, Campbell, CA) together with Nano-11 in 10 mM Tris-saline buffer (pH 7.4). 
After three weeks, mice received a second injection with the same formulation, and 
serum samples were collected two weeks later. Antigen-specific antibody titer was 
decided by ELISA: Ninety-six well plates were coated overnight at     C with antigen in 
carbonate buffer at pH 9.6. The wells were then washed with 0.05% Tween in PBS (PBS-
T), blocked with 1% (w/v) BSA/PBS-T for 1 h at 37 ◦C, and incubated with serial dilutions 
of serum samples in blocking bu er in duplicates for   h at 37   C. This was followed by 
peroxidase-conjugated goat anti-mouse IgG (Sigma) and substrate (TMB, Sigma). After 
incubation in the dark at room temperature for 20 min, the reaction was stopped by 50 
μL of 2 M sulfuric acid. The absorbance was read at 450 nm in a microplate reader 
(BioTEK,Winooski, VT). Titers were calculated as the dilution at which the OD reading 
reached 0.05. 
2.2.13 Light microscopy and immunofluorescence of the injection sites 
Mice were injected in the left quadriceps muscle with 50 µL of a formulation containing 
aluminum hydroxide (120 µg Al3+ /dose) and 5 µg OVA in 0.01M Tris buffered saline and 
in the right quadriceps muscle with 50 µL of a formulation containing 200 µg Nano-11 
and 5 µg OVA in 0.01 M Tris buffered saline. Two weeks after injection, mice were 
euthanized and injection sites were fixed in formalin. Hematoxylin and eosin-stained 
images were captured with a Nikon microscope and Spot camera (Nikon, Tokyo, Japan). 






with AF647-labeled Nano-11 and OVA. At indicated time points injection sites were 
collected and analyzed as described previously 86. 
2.2.14 Statistical Analysis 
Data are presented as mean ± SEM. The statistical significance of differences between 
treatments was determined using a one-way AN VA with Tukey’s post-hoc analysis. 
Differences between serum antibody titers were compared after log2 transformation. 
2.3 Results and discussion 
2.3.1 Physical characterization of Nano-11 
Examination of a Nano-11 suspension by TEM revealed spherical particles with an 
irregular surface, giving them a cauliflower-like appearance (Figure 2.2). The particles 
were single, occasionally in pairs, and rarely formed larger aggregates. The Z-average 
hydrodynamic diameter of nano-11 ranged from 75 to 80 nm and was not affected by 
the pH (Figure 2.2). The particles were fairly uniform in size ranging from 30 – 110 nm 
(Figure 2.2), consistent with previous publications 352,357. Particle size influences the type 
of cells that are targeted, and the quality and magnitude of the immune response. 
Nanoparticles in the 20–200 nm range are preferentially taken up by dendritic cells 
whereas microparticles (> 0.5 μm in diameter) are taken up by macrophages 310. 
Nanoparticles with a 230 nm diameter induced a stronger immune response than those 
with a diameter of 708 nm 358, and another study found that the strongest immune 
response was induced with 40 nm nanoparticles 327. The zeta-potential values ranged 
from + 7 to + 15 mV, with decreased pH leading to increased zeta-potential. As a 






and negatively charged groups (carboxylate). We consider that the impact of pH on 
zeta-potential was mostly associated with carboxylate groups, which are protonized at 
low pH resulting in reduced negative charge and increased zeta-potential. The positive 
charge is likely the reason for the convenient dispersion of Nano-11 in aqueous system. 
The Nano-11 particles adsorbed ovalbumin which is negatively charged at neutral pH, 
but not lysozyme which is positively charged suggesting that the adsorption is largely 
regulated by electrostatic interactions (Figure 2.2). The irregular surface potentially 
increases the adsorptive surface of Nano-11 and may contribute to its high adsorptive 
capacity. Phytoglycogen nanoparticles are dendrimer-like, because, like dendrimers, 
they have a high molecular density which increases from the center to the surface of the 
particle 353.  
2.3.2 Nano-11 has low cytoxicity 
BMDCs were incubated with increasing concentrations of Nano-11 and cell damage was 
assessed by the concentration of lactate dehydrogenase (LDH) in the supernatant 
(Figure 2.3). A modest increase of LDH was observed at Nano-11 concentrations of 
250 μg/mL and higher indicating that Nano-11 has a low level of cytotoxicity. 
2.3.3 Nano-11 enhances delivery of negatively charged antigen to DCs 
A critical step in the activation of the immune response is antigen uptake and processing 
by DCs. Aluminum-containing adjuvants enhance the uptake of antigens by dendritic 
cells and macrophages 66,359. To examine the effect of Nano-11 on antigen uptake, 
BMDCs were incubated with FITC-labeled OVA and AF647-labeled Nano-11. After 2 h of 






2.4).  Previous studies showed that soluble OVA is taken up by BMDCs via the mannose 
receptor 360. When BMDCs were incubated with Nano-11 adsorbed OVA, the amount of 
OVA inside DCs was greatly increased and nearly every cell contained OVA. OVA and 
Nano-11 colocalized in cells, suggesting that OVA remained associated with Nano-11 
after uptake by DCs (Figure 2.4). 
Flow cytometry was used to quantify the percentage of DCs that had taken up 
OVA/Nano-11 and the amount of antigen inside cells. BMDCs incubated with soluble 
OVA had a modest increase of fluorescence consistent with the confocal microscopy 
results. Following incubation with labeled Nano-11 and OVA, both the green and red 
fluorescence increased indicating that the majority of cells had taken up Nano-11/OVA 
complexes and that Nano-11 enhanced the intracellular delivery of Nano-11 (Figure 2.5). 
Adsorption to Nano-11 also increased the uptake of two other negatively charged 
proteins, alpha-casein and human serum albumin (Figure 2.6). In contrast, the positively 
charged Nano-11 particles did not enhance the uptake of positively charged lysozyme 
(Figure 2.6). Preincubation of BMDCs with cytochalasin D, which disrupts the actin 
filament network of cells, prevented the uptake of nanoparticles suggesting that 
phagocytosis is involved in the particle uptake (Figure 2.7). At present, it is not known if 
specific receptors are involved in the interaction between Nano-11 and cells. In 
aggregate, these experiments demonstrate that Nano-11 enhanced the delivery of 






2.3.4 Nano-11 activates DCs in vitro 
In addition to increasing delivery of antigen to DCs, a successful adjuvant also needs to 
promote their activation during which DCs digest the endocytosed antigen into peptides, 
load them onto MHC II molecules (signal 1), and present them together with 
costimulatory molecules (signal 2) and cytokines (signal 3) to T cells, thus triggering an 
immune response 361.  
Incubation of BMDCs with Nano-11 for two days slightly increased expression of 
CD40 and induced a marked increase of the expression of CD80 and CD86 (Figure 2.8). 
This was not caused by LPS contamination of Nano-11 because a similar increase in 
expression was also observed in DCs derived from bone marrow of C3H/HeJ mice, a 
strain deficient in TLR4 making it unable to respond to LPS, compared with its wild type 
counter mate C3H/HeOuJ mice (Figure 2.9). BMDCs were incubated with different 
concentrations of Nano-11 to examine the effect on cytokine secretion. Nano-11 did not 
induce secretion of TNF by BMDCs (Figure 2.10). However, Nano-11 induced secretion of 
IL-12p40, a component of IL-12p70 and IL-23, in a dose-dependent manner although at 
a much lower level than LPS (Figure 2.10). The biological significance of this is uncertain 
as the concentrations of both IL-12p70 and IL-23 in the supernatants were below the 
detection limit (not shown). The secretion of IL-1β, a major pro-inflammatory cytokine, 
requires priming of cells to induce the transcription and translation of biologically 
inactive pro-IL-1β, followed by cleavage into the active form of IL-1β 362. In the absence 
of priming with LPS, Nano-11 only induced secretion of a small amount of IL-1β. 






dependent fashion (Figure 2.10). At the highest dose (240 μg/mL) used in these 
experiments, the secretion of IL-1β exceeded that induced by aluminum hydroxide 
adjuvant, a potent inducer of IL-1β 355,363. Because the ELISA does not distinguish 
between the inactive 31 kD form of IL-1β and the active 17 kD form, a Western blot was 
used to verify that the measured protein was the 17 kD form of IL-1β (Figure 2.10).  
Cleavage of pro-IL-1β is usually mediated by caspase-1 which is a component of 
an inflammasome complex 362. Indeed, incubation with a caspase-1-specific inhibitor, 
YVAD, blocked the secretion of IL-1β induced by Nano-11 (Figure 2.11). Aluminum 
adjuvants activate the NLRP3 inflammasome and this involves a series of critical steps 
including phagocytosis of the particles, acidification of the phagosome, lysosome 
destabilization and release of cathepsin B into cytosol 22,322. To study which pathways 
are involved in inflammasome activation by Nano-11, we used different inhibitors and 
checked their effect on IL-1β production. One hour before LPS priming, we applied these 
inhibitors to DCs while DMSO was used as a control. As expected, the secretion of IL-1β 
induced by aluminum adjuvants was inhibited by bafilomycin A1, cathepsin B inhibitor 
CA-074 Me, and YVAD (Figure 2.12). In contrast, CA-074 Me and YVAD inhibited IL-1β 
secretion following incubation with Nano-11, but inhibition of endosome acidification 
had no effect (Figure 2.11). The abrogation of IL-1β secretion by CA-074 suggests that 
Nano-11 causes lysosomal rupture resulting in the release of cathepsin B which may 
activate the NLRP3 inflammasome. However, one thing to point out is after this chapter 
was published in Journal of Controlled Release, study showed that CA-074 could impact 






determine the exact mechanism of IL-1β secretion induced by Nano-11. Various nano- 
and microparticles, including poly(lactide-co-glycolide), polystyrene, chitosan and 
carbon nanotubes, can induce IL-1β secretion through the activation of NLRP3 
inflammasomes 365–368. The degree of IL-1β secretion and inflammatory propensity of 
nanoparticles can be altered by modification of the particle surface 366,368. It was 
suggested that only positively charged particles induce IL-1β secretion 367, but this is not 
supported by the induction of IL-1β secretion by negatively charged carbon 
nanoparticles and rod-shaped gold nanoparticles 253,366.  
2.3.5 Nano-11 enhances the antibody response to vaccine antigens 
Mice were injected intramuscularly with either soluble OVA or OVA formulated with 
different doses of Nano-11. The OVA-specific IgG titers after two injections were 
significantly increased for the mice that received Nano-11. There was no significant 
difference in OVA-specific IgG between mice that received 50 μg,  00 μg, or  00 μg 
Nano-11 (Figure 2.13). The majority of IgG antibodies were IgG1 with little production of 
IgG2a antibodies (not shown). The experiment was repeated with a more relevant 
antigen, anthrax recombinant protective antigen (rPA), with similar results (Figure 2.14). 
These results show that Nano-11 strongly enhanced the antibody response to two 
different antigens even at 50 μg Nano-11/dose. During the experiments, none of the 
mice showed any signs of local irritation or systemic discomfort. 
2.3.6 Local inflammation and uptake of Nano-11 at the injection site 
Local inflammation at the site of injection is thought to be important for activation of 






presenting cells 12. AF647-labeled Nano-11 with OVA was injected into one of the 
hindlegs of BALB/c mice and soluble OVA only into the other leg. One day after injection, 
mice were euthanized. Their injection sites were excised, sectioned, and stained with 
monoclonal antibodies to detect inflammatory cells (Figure 2.15). The muscle injected 
with soluble OVA contained few inflammatory cells. In contrast, injection of Nano-11-
OVA induced the accumulation of many inflammatory cells including Mac-2-positive 
monocytes/macrophages, MHCII + cells, and Ly-6G + neutrophils. The macrophage 
marker F4/80 did not detect any cells in the injection site, suggesting that most of the 
Mac-2 + cells were monocytes that express low levels of F4/80. The Mac-2 + and 
MHCII + cells contained intracellular Nano-11, indicating that they are the main cell 
types that took up Nano-11 in vivo. The relatively large number of monocytes and fewer 
neutrophils is different from the early inflammatory response following injection of 
aluminum adjuvant in which neutrophils are the most abundant cell type 86. The 
injection sites were also examined two weeks following injection of either aluminum 
hydroxide adjuvant or Nano-11 with OVA. There was extensive granulomatous 
inflammation in muscle injected with aluminum adjuvants and much less inflammation 
following injection of Nano-11 (Figure 2.16). The granulomatous inflammation induced 
by aluminum adjuvant was comprised of extensive aggregates of macrophages 
containing aluminum adjuvant and scattered eosinophils. The Nano-11 injection site 
contained relatively few macrophages arranged in slender cords in the connective tissue 






induced by Nano-11 is transient and resolves more quickly than the injection site 
reaction induced by aluminum hydroxide adjuvant. 
2.4 Conclusion 
Nano-11 is a plant-derived nanoparticle with strong immunostimulatory properties. The 
strong adjuvant effect on the antibody response in vivo is associated with a mild 
transient inflammatory response. In vitro studies suggest that Nano-11 enhances the 
immune response at least in part by efficient delivery of antigens to dendritic cells and 
direct activation of dendritic cells. Nano-11 appears to be a safe and effective adjuvant. 
The raw material for Nano-11 is readily available, and the preparation of these 


















Figure 2.2 Physical characterization of Nano-11 nanoparticles. 
(A) TEM of a 0.01% (w/v) solution of Nano-11. The size bar is 50 nm. (B) Diameter of 
Nano-11 as determined by dynamic light scattering. (C) Zeta potential of Nano-11. (D) 
Adsorption of negatively charged ovalbumin (OVA) and lack of adsorption of positively 







Figure 2.3 Cytotoxicity of Nano-11. 
BMDCs were incubated for 48 h with Nano-11 at the indicated concentrations, and the 










Figure 2.4 Uptake of antigen and Nano-11 by BMDCs. 
BMDCs were incubated for 2 h with soluble FITC-labeled ovalbumin (OVA), with AF647-
labeled Nano-11 or ovalbumin adsorbed to Nano-11; labeled with phalloidin (actin) and 
DAPI (nucleus), and examined by confocal microscopy. The images are representative of 









Figure 2.5 Nano-11 enhances the uptake of adsorbed antigens. 
BMDCs were incubated for 2 h with soluble FITC-labeled ovalbumin (OVA), AF647-
labeled Nano-11, or ovalbumin adsorbed to AF647-labeled Nano-11, and examined by 















medium antigen Antigen + Nano-11 
 
Figure 2.6 Nano-11 enhances the uptake of adsorbed antigens. 
BMDCs were incubated for 2 hours with soluble FITC-labeled α-casein, FITC-labeled 
human serum albumin (HSA) or FITC-labeled lysozyme alone or combined with Nano-
11, and examined by flow cytometry. Casein and HAS are negatively charged at neutral 
pH and adsorb to positively charged Nano-11. Lysozyme is positively charged and does 














Figure 2.7 Preincubation of dendritic cells with cytochalasin D prevents uptake of 
Nano-11. 
Dendritic cells were incubated for 1 h without (A) or with (B) cytochalasin D before 
adding AF647-labeled Nano-11. After 2 hours, cells were fixed and stained with 










Figure 2.8 Nano-11 enhances the expression of CD80 and CD86 on DCs.  
DCs were incubated with either 250 μg/mL Nano-11 (black line) or medium control (gray 
line) for two days and the expression of CD40, CD80, and CD86 was measured by flow 







Figure 2.9 Nano-11 enhances the expression of CD80 and CD86 on DCs from mice deficient in 
the expression of TLR4. 
DCs were incubated with either 250 µg/mL Nano-11 or medium control for two days and the 
expression of MHC II, CD80, and CD86 was measured by flow cytometry. The increased 
expression in TLR4-deficient cells indicates that this effect is not caused by inadvertent exposure 








Figure 2.10 Nano-11 induces secretion of IL-1β and IL-12p40. 
BMDCs were incubated with medium, LPS (100 ng/mL) or Nano-11 at 60, 120 and 
240 μg/mL for   days and supernatants were analyzed for cytokines. (A) Nano-11 does 
not induce significant secretion of TNF. *p < 0.05 LPS vs. medium; (B) Nano-11 induces 
increased secretion of IL-12p40. *p < 0.05 vs. medium; (C) IL-1β was induced in BMDC 
primed with LPS and exposed to aluminum hydroxide adjuvant (AH) and Nano-11. 
*p < 0.05; (D) the secreted IL-1β is 17 kD as indicated by the immunoblot. Bars represent 









Figure 2.11 Secretion of IL-1β by Nano-11 is dependent on cathepsin B and caspase-1.  
BMDCs were incubated with the indicated chemicals followed by LPS and Nano-11. 
Supernatants harvested after 48 h were analyzed for IL-1β. Bars represent the 







Figure 2.12 Aluminum hydroxide adjuvant induces secretion of IL-1β in LPS-primed 
BMDCs. 
The secretion is inhibited by inhibitors of cathepsin B (CA-074 Me), lysosomal 









Figure 2.13 Nano-11 enhances the antibody response to adsorbed OVA. 
Mice were injected twice with Nano-11 at the indicated dose and  0 μg/dose 
ovalbumin (OVA). The antibody titer was determined by ELISA. Box indicates 5-95% 










Figure 2.14 Nano-11 enhances the antibody response to adsorbed rPA. 
Mice were injected twice with Nano-11 at the indicated dose and 2 μg/dose 
recombinant protective antigen (rPA). The antibody titer was determined by ELISA. Box 









Figure 2.15 Nano-11 induces inflammation and uptake by Mac-2 + monocytes and 
MHCII + cells. 
Skeletal muscle was collected 24 h after injection of AF647-labeled Nano-11 with OVA or 
soluble OVA, and labeled with antibodies against monocytes (Mac-2), MHCII, 
neutrophils (1A8), and macrophages (F4/80). Arrows point to cells Mac-2 + and MHCII + 










Figure 2.16 ano-11 causes less residual inflammation compared with aluminum 
hydroxide adjuvant (AH).  
Injection sites were collected 2 weeks after injection, and sections were stained with 
H&E. The images were collected with a 10 × objective, inset 40 ×. * = inflammation; 










CHAPTER 3. ALPHA-D-GLUCAN NANOPARTICULATE ADJUVANT INDUCES A TRANSIENT 
INFLAMMATORY RESPONSE AT THE INJECTION SITE AND TARGETS ANTIGEN TO 
MIGRATORY DENDRITIC CELLS 
3.1 Introduction 
Modern vaccines are increasingly formulated with antigens consisting of subunits of 
microbial pathogens to allow for a more focused immune response while increasing the 
safety compared with whole killed and attenuated pathogens 369. These subunit 
vaccines usually require adjuvants in order to stimulate  an effective immune reaction 
121314. Human vaccines are usually formulated with aluminum-containing adjuvants. 
Although they have an excellent safety record and are generally effective at inducing an 
antibody response, aluminum adjuvants have several drawbacks including poor 
stimulation of cell-mediated immune responses, susceptibility to freezing, and 
occasionally adverse reactions at the injection site 32222.  Veterinary vaccines often 
contain adjuvants other than aluminum adjuvants including water-in-oil emulsions and 
saponins, but these are often associated with significant local reactions at the injection 
site. Thus, there is a need for new safer and more effective adjuvants to protect both 
human and animal populations.  
Nanoparticles refer to any particulate materials that are less than one micrometer 






easily recognized and endocytosed by immune cells, making them good 
candidates as vaccine adjuvants 370. Indeed the very first report of medical application of 
nanoparticles, published in 1976, described the use of polymeric micelle nanoparticles 
as an adjuvant 27. Further progress on nanotechnology, including development of 
biodegradable nanoparticles and various methods to functionalize their surface, has 
stirred huge interest in the vaccine community to build the next generation of adjuvant 
based on nanoparticle platforms 28. 
Nanoparticles can help boost the immune response in multiple ways. They can 
induce inflammatory reaction at the injection site, which recruits immune cells to the 
proximity of antigens, a phenomenon termed “reverse targeting”14. Through 
encapsulating antigen or absorbing it on their surface, nanoparticles can enhance the 
uptake of antigen by APCsand subsequently promote their activation. After activation, 
these antigen-containing APCs migrate to the draining lymph node to activate antigen-
specific T cells and drive the adaptive immune response. Alternatively, some 
nanoparticles drain via the lymph to the lymph node, where they can be picked up by 
lymphoid tissue DCs 26. Clearance of nanoparticles is a concern for medical application, 
and wide tissue distribution and long term deposition following injection of these 
particles are not desirable.  Phagocytic cells recruited to the injection site through 
“reverse targeting” can phgocytize and subsequently digest the nanoparticles if they are 
biodegradable. Alternatively, nanoparticles could be excreted via the kidneys or liver 336. 
Phytoglycogen nanoparticles are polysaccharide structures derived from plants. 






The deficiency of a starch debranching enzyme results in the formation of highly 
branched, dendrimer-like PG nanoparticles to replace starch granules 353,354. The surface 
of PG nanoparticles can be chemically modified to give them different chemical and 
biological properties. We recently reported that a functionalized PG nanoparticle 70-80 
nm in size with positive charge and an amphophilic surface, termed Nano-11,  enhanced 
the delivery of absorbed antigen to and subsequently activate DCs in vitro 371. 
Formulation of Nano-11 with different antigens significantly increased the immune 
response, demonstrating its adjuvant effect. However, the distribution and fate of 
Nano-11 after injection are unknown. Here we investigated the mechanism of Nano-11 
clearance after administration, its interaction with immune cells in vivo, and the effect it 
exerts on the delivery of coinjected antigen to the draining lymph node. 
3.2 Materials and methods 
3.2.1 Mice and immunization 
Six week old female BALB/c mice were purchased from Harlan, Inc. (Indianapolis, IN) 
and housed with food and water ad libitum. All procedures were approved by the 
Purdue University Animal Care and Use Committee. Mice were immunized on both calf 
muscles with a volume of 50 µL each containing 100µg/mL Alexa Fluor 647-labeled OVA 
(Sigma, St. Louis, MO) or OVA (Invivogen, San Diego, CA) with or without 2 mg/mL Alexa 
Fluor 647-labeled or nonlabeled Nano-11, or 1mg/mL aluminum hydroxide adjuvant 






3.2.2 Preparation of Nano-11 and Alexa Fluor 647-labeled Nano-11 
Preparation of Nano-11 has been described previously 371. To label Nano-11 with Alexa 
Fluor 647 (ThermoFisher, Waltham, MA), 1 g of Nano-11 was first acidified in 6mL of 2.5 
M HCl for 30 minutes with constant agitation. Excessive acid was initially washed by the 
addition of 20 mL of a 90% isopropanol solution (v/v) followed by constant agitation 2 
hours.  This mixture was then centrifuged at 3,000 g for 10 minutes and the supernatant 
was decanted.  Further washing was performed by repetitive resuspension in new 
isopropanol solution, agitation for 20 minutes, and centrifugation. The sample was 
washed two more times after the decanted supernatant tested negative for chloride 
ions (i.e., no observation of AgCl white haze) upon the drop-wise addition of 0.1 M 
AgNO3.  Thereafter, the dry acidified Nano-11 powder was obtained by rinsing the 
mixture two times using 100% ethanol, constant agitation for 1 hour, centrifugation, 
and grinding. After that, 12 mg of acidified Nano-11 was dissolved in 600 µL of 50 mM 
solution of 2-(N-morpholino)ethanesulfonic acid (MES) buffer.  Twelve mg of 1-ethyl-3-
(3-dimethylamino- propyl)carbodiimide (EDAC) was dissolved in 1.2 mL of MES buffer 
and then added to the Nano-11 dispersion. One mg of Alexa Fluor 647 was dissolved in 1 
mL of MES buffer and an aliquot of 120µL was added immediately after EDAC and Nano-
11 were mixed.  This mixture was then incubated under constant agitation for 4 hours at 
room temperature and 5 hours at 4°C.  After the labeling, unbound Alexa Fluor 647 dye 
was separated from labeled Nano-11 through centrifugal infiltration with Nanosep® (Pall 
Co, Port Washington, NY) at 12,000 g for 20 minutes followed by additional seven times 






labeled Nano-11 was final purified with three rounds of dialysis wash (3 h, 3 h, &18 h) 
with 10K MWCO Slide-A-Lyzer™    dialysis cassettes (ThermoFisher, Waltham, MA) in 
MES buffer containing 2ppm NaN3. The final product was stored at 4°C for future use.  
3.2.3 In vivo imaging 
One day before in vivo imaging, mice were shaved and treated with Nair to remove hair 
from the lower part of the body. After immunization mice were imaged on an IVIS® 
Lumina II In Vivo Imaging System (PerkinElmer, Waltham, MA). Mice were anesthetized 
through isoflurane inhalation during imaging and fluorescent signals in the images were 
analyzed by Living Image software (PerkinElmer, Waltham, MA). 
3.2.4 Injection site study 
At the indicated times after immunization, mice were euthanized by CO2 asphyxiation 
and the injection site samples were excised. The tissues  were fixed in 4% 
paraformaldehyde for three hours, dehydrated in 30% sucrose solution overnight, 
embedded in Optimal Cutting Temperature medium, snap frozen in liquid nitrogen and 
stored at -80   C. Eight micrometer thick sections of the tissue were obtained with a Leica 
CM1860 cryostat  (Leica Biosystem, Buffalo Grove, IL). Sections were stained with the 
following antibodies:  Biotinylated anti-I-A/I-E, anti-Ly-6G, anti-Mac-2, anti-Ly-6C (all 
from Biolegend, San Diego, CA). The antibodies were detected with Alexa Fluor 488-
conjugated streptavidin (Jackson Immunoresearch Laboratory, West Grove, PA). 
Eosinophils were stained with phenol red 372. Sections were then embedded in Prolong 
Gold antifading with DAPI (Invitrogen, Carlsbad, CA), coverslipped, sealed, and stored at 






high-power field on a fluorescence microscope (Nikon E400).  Confocal images of the 
injection sites were obtained with a Nikon A1R MP microscope (Nikon).  
3.2.5 Flow cytometry detection of Nano-11 and antigen in lymph nodes 
Iliac lymph nodes were excised from immunized mice and immediately immersed in 
HBSS medium and put on ice. Lymph nodes were then treated with 1mg/mL Collagenase 
D (Roche Diagnos cs, Indianapolis, IN) at 37   C for 20 min to release cells. Cells were 
washed with PBS containing 2 mM EDTA, blocked with 1% normal rabbit serum, and 
stained with the following antibodies and reagents: Zombie Violet, biotinylated anti-
Ly6G, biotinylated anti-Ly6C, Alexa Fluor 488 or PerCP-Cy5.5-conjugated anti-CD11c, PE-
conjugated anti-I-A/I-E, PE/Cy7-conjugated anti-CD86, Alexa Fluor 488-conjugated F4/80 
(all from BioLegend, San Diego, CA), and PE-conjugated anti-Siglec F (BD Bioscience, San 
Jose, CA). Biotinylated antibodies were detected with Alexa Fluor 488 or APC-conjugated 
streptavidin.  After staining, cells were fixed in 2% paraformaldehyde. Cells were 
examined in a Canto II flow cytometer (BD Bioscience, San Jose, CA), and data were 
analyzed with FlowJo software (FlowJo, Eugene, OR). 
3.2.6 Statistical analysis 
The bars in the graphs represent the mean ± SEM. The statistical significance of 
differences between different groups was determined with one-way ANOVA with 
Newman-Keuls post-hoc analysis for multiple group comparison or Student’s test for 







3.3.1 Nano-11 does not disperse after injection and is cleared from the injection site 
over time. 
A whole mouse imaging system was used to study the distribution of Nano-11 after 
injection over a three week time period. Following injection of Alexa Fluor 647-labeled 
Nano-11 into the calf muscles of both legs, fluorescent signal could be readily detected 
at the injection site (Figure 3.1A). The signal was mostly confined to the injection site 
and its intensity gradually decreased over the observation period. To confirm that the 
injected nanoparticles did not distribute to internal organs, major organs from mice 
were excised at the end of the observation period and examined under the imager. 
Fluorescent signal was only detected at the injection sites and not in any internal organs 
(Figure 3.1B). Fluorescent signals were also not detected in any major internal organs on 
Day 1 and Day 7 (Data not shown). Quantification of the fluorescence intensity at 
different time points after immunization showed that the fluorescent signal was 
strongest when labeled Nano-11 was first injected into the muscle, rapidly decreased  
on Day 1 before a slight increase on Day 2. After Day 2, the fluorescent signal steadily 
decreased over time and by Day 21 only about 20% of the original signal could be 
detected (Figure 3.1C).   
3.3.2 Nano-11 induces a transient inflammatory response at the injection site. 
Inflammation induced at the site of vaccination plays an important role in the initiation 
of the immune response, but excessive or persistent inflammation may lead to local 






11 with 10 µg OVA were investigated at different time points after injection (Figure 3.2). 
Inflammatory cells appeared at the injection site starting from 2 h after immunization 
and their number rapidly increased until Day 2. After Day 2, the number of inflammatory 
cells gradually decreased and few cells remained by Day 21. Mac-2+ inflammatory 
macrophages and monocytes comprised the majority of inflammatory cells since 6h 
after immunization. A moderate number of neutrophils were present at 6 h and their 
number dropped sharply after Day 1.  A few antigen presenting cells (MHCII+) and 
eosinophils first appeared at 6 h and their numbers gradually increased until Day 
7.Canonical monocytes (Ly6C+) appeared early at the injection site and their number 
decreased by Day 7. The relative abundance of Mac-2+ cells contrasted with the 
injection sites of aluminum-containing adjuvants in which neutrophils were the most 
abundant cells on Days 1 and 2 after immunization (Figure 3.3).  
3.3.3 Nano-11 is taken up by antigen presenting cells, macrophages, and monocytes. 
To determine which types of cells take up Nano-11, we injected 200 µg Alexa Fluor 647-
conjugated Nano-11 with 10 µg OVA into mice and excised the injection sites at 6h, Day 
1, Day 2, and Day 7 (Figure 3.4). At 6 h, Nano-11 was mainly extracellular, but on Day 1 
most of the red fluorescence was intracellular indicating active phagocytosis of Nano-11. 
Nano-11 was present in MHC II+ antigen presenting cells at all time points examined.   
Nano-11 was also found inside Ly6C+ cells at 6 h, Day 1, and Day 2. The number of Ly6C+ 
cells was very small on Day 7, and none of them contained Nano-11. Mac-2+ cells with 
intracellular Nano-11 were first observed on Day 1. By Day 2, Mac-2+ cells were the most 






Nano-11 was in monocytes or antigen presenting cells. There was no evidence of uptake 
of Nano-11 by neutrophils at any time point. Nano-11 was also not detected in muscle 
or fibroblast cells (data not shown). 
3.3.4 Nano-11 is transported mainly by migratory dendritic cells to the draining lymph 
node. 
Antigens can reach draining lymph nodes after uptake by DCs or by diffusion in lymph 
followed by uptake of lymph node resident DCs. We studied the type of Nano-11-
containing cells in the draining lymph nodes at different time points after immunization. 
After injection of 200 µg Alexa Fluor 647-conjugated Nano-11 with 10 µg OVA, whole 
iliac lymph node cells (around two million cells in total) were harvested and stained to 
detect Nano-11-containing cells. Among the myeloid cells (identified as FSCmedium-high and 
SSCmedium-high) in the lymph node, those containing Nano-11could be differentiated into 
three subpopulations (Figure 3.6).  Migratory DCs (MigDCs), which refer to the DCs that 
take up antigen from the injection site and migrate to the lymph node, were identified 
as MHCIIhigh and CD11cmedium cells. The second population was MHCIImedium and CD11chigh 
cells, which represent the lymphoid tissue resident DCs (LTDCs) 83,373. The third 
population was MHCIIlow-medium and CD11clow and these were mainly monocytes and 
macrophages (Figure 3.7).  
Cells containing Nano-11 were detected throughout the first seven days after 
immunization (Figure 3.8A), with the highest amount of Nano-11 detected on Day 2 
when more than 3% of all myeloid cells in the lymph node were Nano-11+ (Figure 3.8B). 






positive cells. Macrophages and monocytes comprised 10-30% of the Nano-11-positive 
cells and less than 10% of Nano-11 was in LTDCs (Figure 3.8C). A small population of 
neutrophils and eosinophils was present in the draining lymph node and they did not 
contain Nano-11 (Figure 3.9). 
3.3.5 Nano-11 facilitates the targeting of coinjected antigen to MigDCs and enhances 
its transportation to the draining lymph node.  
We previously showed that  negatively charged antigens could be absorbed onto the 
surface of Nano-11 and that such absorption enhanced uptake of antigen by DCs in vitro 
371. To determine if Nano-11 also facilitated the transport of antigen to the draining 
lymph node in vivo, 10 µg Alexa Fluor-647 labeled OVA alone or combined with 200 µg 
Nano-11 was injected into mice and iliac lymph nodes were harvested on Day 1 and Day 
2 after immunization.  For comparison, labeled OVA was adsorbed to 200 µg AH, which 
also increases antigen uptake by DCs 66. On Day 1 after immunization, around 1.5% of 
myeloid cells in the draining lymph node contained OVA for all three formulations 
(Figure 3.10A), indicating transportation of antigen to the lymph node occurs with or 
without adjuvants. However, on Day 2 after immunization, the percentage of OVA-
containing myeloid cells in the lymph node dropped sharply to only about 0.5% in mice 
injected with OVA only, while for both Nano-11 and AH-adjuvanted vaccines, the 
percentage of OVA containing myeloid cells remained at around 1.5% (Figure 3.10B). 
Although OVA was present in about the same percentage of cells in the lymph node for 
all three formulations on Day 1, the mean fluorescence intensity (MFI) of OVA in cells 






formulations (Figure 3.10A, 3.11A), suggesting Nano-11 efficiently enhanced the 
delivery of antigen to APCs on a per cell basis. The MFI was much lower for mice 
injected with antigen only on Day 2, but it remained high for adjuvant-containing 
formulations with a significantly higher MFI for the Nano-11 formulation compared with 
AH (Figure 3.10B, 3.11A). In addition, Nano-11 increased the uptake of OVA by MigDCs 
compared with other formulations (Figure 3.10B, 3.11B).  
In order to function as effective antigen-presenting cells, DCs need to increase 
the expression of costimulatory molecules such as CD86. The expression level of CD86 
on the three main types of OVA+ myeloid cells was examined on Day 2 after injection. 
MigDCs had the highest level of CD86, followed by LTDCs, and then monocytes and 
macrophages (Figure 3.11C). 
After injection of adjuvanted vaccines, MigDCs in the draining lymph node can be 
further divided into three subpopulations, namely migratory CD α+ DCs that are CD11b- 
CD8+Ly6C-, migratory CD11b+ DCs that are CD11b+CD8-Ly6C-, and monocytes derived 
MoDCs that are CD11b+Ly6C+  330. The majority of OVA was in CD11b+ DCs while some 
OVA was in MoDCs following injection of Nano-11 adjuvanted OVA. Among OVA-
negative MigDCs, more CD α+ type DCs and fewer MoDCs were present (Figure 3.11D). 
This suggests that Nano-11 targets antigen to CD11b+ DCs and MoDCs.  
3.3.6 Nano-11 retains antigen at the injection site. 
OVA-containing cells appeared in the draining lymph node for a shorter period of time 
after injection of soluble OVA compared with adjuvanted OVA. We hypothesized that 






prolonged the supply of antigen to the draining lymph node. To test this, we utilized 
whole mouse imaging again to assess how long Alexa Fluor-647 labeled OVA stayed at 
the injection site with different formulations (Figure 3.12). Immediately after 
immunization, OVA was readily detected at the injection site with all three formulations. 
One day after immunization soluble OVA was present at a lower level compared with 
the adjuvanted formulations.  However, by Day 2 soluble OVA was barely detectable at 
the injection site, corresponding to the rapid decrease in the lymph node on Day 2, 
while the presence of adjuvanted OVA remained high. On Day 7, no soluble OVA was 
detected at the injection site but there was still residual OVA when formulated with AH 
or Nano-11. This confirmed that Nano-11 retained antigen at the injection site at a 
comparable level as AH for the first seven days following injection. 
3.4 Discussion 
Nanotechnology holds great potential for the development of improved vaccine 
adjuvants and delivery systems. In order to develop nanoparticles as safe and effective 
adjuvants, it is important to understand the fate and biodistribution of the nanoparticles 
in vivo 26. The interaction of nanoparticles with cells, extracellular matrix and plasma 
proteins depends on their size, shape, surface charge, chemical composition, and 
toxicity 26,374. We recently reported that Nano-11, positively charged alpha-D-glucan 
dendrimer nanoparticles, enhances the immune response when combined with 
different protein antigens 371. In vitro experiments with bone marrow-derived DCs 
demonstrated that Nano-11 is readily phagocytized and enhances the uptake of 






increased expression of costimulatory molecules CD80 and CD86, and secretion of IL-1β 
371. In the current series of experiments we assessed the effect of Nano-11 on DCs in 
vivo and the biodistribution following intramuscular injection.  
Vaccine adjuvants act locally at the site of injection and should enhance the 
transport of vaccine antigens to the draining lymph node where the adaptive immune 
response is initiated. It is preferable that the adjuvant does not reach other organs and 
tissues to avoid systemic effects.  Assessment of the distribution of fluorochrome-
labeled Nano-11 indicated that the adjuvant remains largely localized to the site of 
injection. A small amount of the adjuvant reached the draining lymph nodes as 
demonstrated by imaging of excised lymph nodes and analysis of dendritic cells and 
macrophages by flow cytometry. There was no evidence of accumulation of Nano-11 in 
other organs including the lungs, liver, and kidneys. This is consistent with the lack of 
clinical or histologic evidence of disease in injected mice and supports the safety of 
these nanoparticles as vaccine adjuvants. The fluorescent signal at the injection site 
decreased rapidly during the first day and was higher on Day 2 after injection. We 
speculate that the lower level of fluorescence on Day 1 compared with Day 2 is the 
result of a temporary edema associated with the local inflammatory response to the 
injected nanoparticles. The fluid accumulated in the edema could absorb some of the 
fluorescent signals that traveled through it, leading to a temporary drop of the 
fluorescent signal. The fluorescence gradually decreased over time indicating that the 






up by macrophages accumulating at the site of injection, and it is likely that they are 
degraded intracellularly. 
Nano-11 is positively charged and adsorbs negatively charged protein antigens 
such as OVA similar to positively charged aluminum hydroxide adjuvant 371. Imaging of 
fluorescently labeled OVA indicated that soluble OVA rapidly disappears from the 
injection site, but adsorption to either aluminum hydroxide adjuvant or Nano-11 retains 
the antigen at the injection site for several days. This is consistent with earlier studies on 
aluminum adjuvants 303. The retention increases the period of time during which antigen 
is available for phagocytosis by antigen-presenting cells that are recruited to the 
injection site and may be important for the adjuvant effect of Nano-11. 
Adjuvants often trigger a local inflammatory response at the site of injection as a 
result of direct activation of inflammatory cells and indirectly by the mechanical trauma 
associated with the injection of particulate material or emulsions. The inflammation 
allows the recruitment of antigen-presenting cells to the injection site where they can 
take up the vaccine antigens (“reverse targeting”). Previous studies showed that Nano-
11 induces the secretion of IL-1β by dendritic cells in a caspase-1 dependent fashion. IL-
1β is a potent pro-inflammatory stimulus and this indicates that Nano-11 has the 
intrinsic property to induce an inflammatory response. Similar to Nano-11, aluminum 
adjuvants also induce IL-1β secretion by dendritic cells 90,355,363.  However, the 
inflammatory response induced by aluminum adjuvanted vaccines is characterized by an 
early infiltration of many neutrophils in comparison with Nano-11 86. Neutrophils 






damage through the release of proteolytic enzymes and reactive oxygen species 375,376. 
It has been suggested that neutrophil accumulation is detrimental to the immune 
response to vaccines because they compete for vaccine antigens with antigen-
presenting cells 377, although depletion of neutrophils prior to vaccination did not affect 
the antibody response to aluminum adjuvanted antigens 86. Nevertheless, 
administration of antigens with Nano-11 may induce less tissue damage and increase 
the availability of antigens for antigen-presenting cells in comparison with aluminum 
adjuvants.  The limited tissue damage induced by Nano-11 may also contribute to the 
diminishiment of the inflammation after Day 2 and a substantial decrease of 
inflammatory cell number at the injection site by Day 21. This is in contrast to the long 
lasting granulomas induced by aluminum adjuvants, although such granulomas are 
rarely associated with clinical symptoms 87.  
Following injection of fluorochrome-labeled Nano-11, fluorescent cells appeared 
in the draining lymph node on Day 1, increased in number on Day 2, and had nearly 
complete disappeared on Day 7. The majority of Nano-11 positive cells were identified 
as migratory DCs suggesting that the cells picked up Nano-11 in tissues and migrated to 
the lymph node. The uptake of particulate material by DCs is influenced by the size, 
shape, surface charge and chemical composition 26. Smaller nanoparticles are 
preferentially taken up by DCs, whereas microparticles are preferentially phagocytized 
by macrophages 313,327. Cationic particles are more efficiently taken up than neutral 
charged or anionic particles 313. Nanoparticles can enhance the delivery of antigens to 






DCs in the lymph node following injection of soluble OVA or combined with either Nano-
11 or aluminum adjuvant showed that both adjuvants increase the number of OVA-
containing DCs in the lymph nodes. However, Nano-11 induced a greater uptake of OVA 
in comparison with aluminum adjuvant on a per cell basis. There are several 
explanations for the increased efficiency of the delivery of OVA to the lymph node by 
Nano-11. First, aluminum hydroxide adjuvant forms large aggregates, about 17 µm in 
size, which are not easily phagocytized in contrast to the 70-80 nm Nano-11 
nanoparticles. Secondly, as discussed above, the accumulation of neutrophils at the 
injection site induced by aluminum adjuvants may interfere with antigen uptake by DCs. 
Thirdly, Nano-11 provides a stronger maturation stimulus to DCs as indicated by the 
increased expression of costimulatory molecules which may enhance the migration to 
the draining lymph node. Following injection of Nano-11 with OVA, most of the OVA-
containing cells were migratory DCs with high expression of CD86 and which were 
comprised predominantly of CD11b+ DCs and moDCs. These subpopulations of DCs are 
highly effective in inducing the adaptive immune response 378–380. 
In summary, we have demonstrated that positively charged α-D-glucan 
nanoparticles (Nano-11) induce a local inflammatory response at the injection site and 
effectively targets antigen to migratory DCs.   The inflammation resolves within two to 
three weeks and there is no evidence of long term deposition or systemic distribution of 
the nanoparticles. These findings support the further development of Nano-11 as a safe 








Figure 3.1 Nano-11 was retained at the injection site and cleared with time. 
(A) Mice were injected in both calf muscles with 200 µg Alexa Fluor 647-labeled Nano-
11 (1 and 2) or nonlabeled Nano-11 (control) with 1 0µg OVA and imaged under a 
fluorescence imager at different time points. (B) Internal organs (from top to bottom: 
heart, lung, spleen, liver, kidneys, iliac lymph node, popliteal lymph nodes, and injection 






Fluorescence intensity of the injection site over time expressed as percentage of the 










Figure 3.2 Nano-11 injection induced transient inflammation at the injection site. 
(A) Injection sites were collected at different time points after intramuscular injection of 







imageswere collected with a 40X objective lens on a confocal microscope and are 
representative of four independent experiments. Bar=50 µm. (B) Density of different 
inflammatory cells at the injection site over time. The data indicate the number of cells 













Figure 3.3 Neutrophils at the injection sites on Day 1 and Day 2 for either Nano-11 or 
AH injected mice.  
Confocal images were taken under a 40X objective lens on a confocal microscope and 










Figure 3.4 Nano-11 is taken up by Mac-2+ cells, MHCII+ cells, and monocytes at the 
injection site. 
 Mice were injected with 200 µg Alexa Fluor 647-labeled Nano-11 with 10 µg OVA and 
tissue samples were labeled as indicated. Confocal images were collected with a 60X 










Figure 3.5 Most Nano-11 at the injection site is inside Mac-2+ cells by Day 2.  
Confocal images were taken under a 60X objective lens and are representative of two 










Figure 3.6 Gating strategy for detecting and phenotyping Nano-11-containing myeloid 
cells in the draining lymph nodes. 
Gating strategy is demonstrated on a lymph node sample harvested on Day 2. 
Representative of three independent experiments is shown here. A whole population of 










Figure 3.7 Phenotyping for the MHCIIlow-mediumCD11cmedium population in the draining 
lymph node.  










Figure 3.8 Nano-11 was actively transported by APCs to the draining lymph node.  
(A) Detection and phenotyping of Nano-11-containing myeloid cells at different time 
points in the draining lymph node. Data are representative of three independent 
experiments. (B) Percentage of Nano-11-containing cells among all myeloid cells in the 
draining lymph node over time. (C) Distribution of Nano-11 in different subtypes of APCs 











Figure 3.9 Absence of Nano-11 from neutrophils and eosinophils in the draining lymph 
node.  



















Detection and phenotyping of OVA+ cells in the draining lymph nodes of mice injected 
with 10µg Alexa Fluor 647-conjugated OVA alone or adjuvanted with either AH (200 µg) 











Figure 3.11 Nano-11 improves antigen targeting in the lymph nodes.  
(A) Mean fluorescence intensity of OVA in OVA-containing cells in the draining lymph 
node on Day 1 and Day 2 with mice injected with different formulations. (B) Percentage 
of MigDCs among OVA-positive cells in the draining lymph nodes of mice injected with 
different formulations. For A and B, columns are mean ± SEM of six mice. *p<0.05 (C) 
Expression of CD86 on different types of OVA+ cells in the lymph node. (D) Phenotyping 
of OVA+ and OVA- MigDCs in the draining lymph node. For C and D, lymph nodes were 
harvested two days after injection of Alexa Fluor 647-labeled OVA adjuvanted with 










Figure 3.12 Nano-11 increases retention of antigen at the injection site.  
Mice were injected with 10μg of Alexa Fluor   7-conjugated OVA alone or adjuvanted 
with either AH or Nano-11 and examined with a fluorescence imager over time. Data are 







CHAPTER 4. CELLULAR UPTAKE MECHANISM AND INTRACELLULAR KINETICS OF 
NANO-11 
4.1 Introduction 
Nanoparticles are a promising platform upon which to build the next generation of 
adjuvants 4,6,26. They enhance the immune responses toward antigens at least in part by 
rendering the adsorbed or encapsulated antigens into particulate form and promoting 
their delivery to immune cells, especially APCs 52,381. 
There are multiple mechanisms APCs can utilize to internalize nanosized particles, 
including phagocytosis, macropinocytosis, clathrin or caveolae-mediated endocytosis, 
and clathrin/caveolae independent endocytosis 310,319,382. Phagocytosis is an 
cytoskeleton-driven mechanism mainly utilized by APCs and other granulocytes to 
internalize particles larger than 0.5 µm and is usually receptor-mediated 317. 
Macropinocytosis is another way for cells to take up large particles around 0.5-5 μm but 
is a non-specific mode of uptake similar to the “drinking” of extracellular fluid along with 
the particles by the cells 383. In addition, there are several endocytosis routes for 
nanoparticles to enter the cells. The best described one involves the forming of a 
basket-like clathrin lattice around the particle-containing pit before the particle is 
internalized. Thus this route is called clathrin-mediated endocytosis. It is usually used to  







caveolae-mediated endocytosis which has the vesicles coated with caveolin dimers and 
is believed to require a GTPase called dynamin. It usually involves uptake of particles 50-
80 nm in size 4. Besides the above mentioned forms of endocytosis, clathrin and 
caveolae independent routes of endocytosis have been reported 320. How nanoparticles 
enter immune cells is affected by factors like their size and charge. Specific routes each 
type of particles use can be investigated through different inhibitory drugs that can 
block particular pathways 314,384. It is important to understand how nanoparticles enter 
the cells because the uptake mechanism of nanoparticles may affect the kinetics and 
fate inside cells for both the adjuvants and their antigen cargo 385,386.  
Once inside the cell, nanoparticle-containing vesicles will gradually mature with a 
decreasing pH value from early endosomes (pH 6.0-6.5) to late endosome (pH 5.2-6.2) 
and eventually fuse with lysosomes (pH 4.5-5.2) 382. The strong acidic lysosomal 
environment along with lysosome-specific proteases and other enzymes result in 
degradation of most of its containments 387,388. However, some internalized 
nanoparticles can be transported back into the extracellular environment. This can 
happen either directly from particle-containing early endosomes, or after the vesicle 
matured into late endosome, in which case particles will be transported first to the Golgi 
apparatus, an endomembrane system that sits at the intersection of secretory and late 
endocytic pathways 388,389. There the nanoparticles will be repackaged into membrane-
bound vesicles for secretion. 
Nano-11 is a dendrimer-like phytoglycogen nanoparticle around 80 nm in size 







negatively charged antigens on its surface and facilitates their delivery to DCs. The 
nanoparticles can also directly activate DCs by both upregulating the expression of 
costimulatory molecules on the cell surface and activating a multi-protein oligomer in 
the cytoplasm called inflammasome that cleave the proinflammatory cytokine IL-1β into 
an active form that is secreted. Unlike the commonly used aluminum adjuvants, injected 
Nano-11 was readily cleared from the injection site within weeks, supporting the 
concept that it is a safe adjuvant to use. However, the mechanism of Nano-11 uptake by 
DCs, the fate of Nano-11-containing vesicles inside cells, and the impact of Nano-11 
internalization on the assembly of functional inflammasome machinery in the cytoplasm 
are not well understood. The current study was designed to address these topics.    
4.2 Materials and methods 
4.2.1 Generation of BMDCs 
Bone marrow cells from the femurs and tibias bones of six to ten week old female 
BALB/c mice were flushed out and incubated in 10 cm petri dishes at a concentration of 
5X105 cells/mL and a volume of 10 mL. The medium was RMPI with 5% FBS 
supplemented with 100 µg/mL streptomycin, 0.25 µg/mL amphotericin B, 2mM l-
glutamine, 50 µM β-mercaptoethanol, and 20 ng/mL  M-CSF in the presence of 5  FBS. 
The petri dishes were incubated at 37   C with 5% CO2 and on Day 3, Day 5, Day 7, and 
Day 9, 5 mL of the medium was replace with fresh medium. On Day 10, 5 mL of fresh 
medium was added to the petri dishes. The cells were harvested on Day 11 and flow 







4.2.2 Immunofluorescence detection of Nano-11 uptake 
BMDCs were seeded at a concentration of 3X105 cells/mL in an eight well chambered 
slide (Sarstedt, Numbrecht, Germany). After cells attaching to the slides, 30 µg/mL 5-(N-
eithyl-N-isopropyl) amiloride (EIPA), 20 µg/mL chlorpromazine hydrochloride, 25 µg/mL 
dynasore hydrate (dynasore), 10 µg/mL nocodazole, or 2 µM cytochalasin D (CytoD) (all 
from Sigma, St. Louis, M ) were added to the wells. Alterna vely, cells were incubated 
at     C for one hour. Alexa Fluor-647 (AF647)-conjugated Nano-11 was then coincubated 
with BMDC at a concentration of 50 µg/mL. After one hour, the cells were washed with 
ice cold PBS to remove the extracellular labeled Nano-11, fixed with 4% 
paraformaldehyde, and stained with wheat germ agglutinin (WGA) (Thermo Fisher 
Scientific, Waltham, MA) to label the cell membrane. Slides were mounted in Gold 
antifading with DAPI (Thermo Fisher Scientific), sealed with coverslips. Images were 
captured on a Nikon A1R MP microscope with a 100X objective lens.  
4.2.3 Flow cytometry detection of Nano-11 uptake 
BMDCs were seeded in 24 well plates at a concentration of 106 cells/mL. Cells were 
treated with di erent endocytosis inhibitors or under     C for one hour and then 
incubated with AF647-labeled Nano-11 at 50 µg/mL for another hour. Cells were then 
washed with ice cod PBS and released from plate bottom with 0.25% trypsion/2.21 mM 
EDTA-containing HBSS (Corning Cellgro, Corning, NY). Released cells were blocked with 1% 
normal rabbit serum and stained with Zomibe Violet and AF488-labeled CD11c (both 
from BD Bioscience, San Jose, CA). Cells were examined on a Canto II flow cytometer (BD 







4.2.4 Immunofluorescence tracing of intracellular Nano-11 
AF647-labeled Nano-11 was incubated with seeded BMDCs in eight well chambered 
slides for 0 min, 10 min, 30 min, or 60 min. Cells were then washed, fixed, permeabilized 
with 0.5% saponin/1% BSA in PBS for 30min at room temperature, and stained with 
AF488-labeled anti-LAMP-1 (eBioscience, San Diego, CA). Slides were then mounted and 
sealed for imaging.   
4.2.5 Inflammasome stimulation and ELISA  
In 96 well plates BMDCs were seeded at a concentration of 5X105 cells/mL. A er adding 
endocytosis inhibitors or incuba on at     C, cells were stimulated with LPS at 100 ng/mL 
for one hour. Nano-11 was added to cells at 200 µg/mL and the cells were left in the 
incubator or fridge for another two days. After two days the plates were centrifuged at 
1,000 rpm for 5 min and the supernatant was harvested. The concentration of IL-1β in 
the supernatant was measured with a mouse IL-1β ELISA kit (eBioscience) following the 
manufacturer’s protocol.  
4.2.6 Data analysis 
Data are presented as mean ± SEM. Differences among groups was determined with a 
one-way AN VA test with Tukey’s post-hoc analysis. Differences were considered 
significant when p-value < 0.05. 
4.3 Results 
4.3.1 Mechanism of Nano-11 uptake by BMDCs 
To inves gate the mechanism of Nano-11 uptake by BMDCs, cells were  rst pretreated 







treatments and their targeted mechanisms are listed in Table 4.1. AF647-labeled Nano-
11 was added to treated cells and incubated for one hour. The cells were washed and 
the cell membrane was stained with WGA. Cellular uptake of Nano-11 after different 
treatments was examined by confocal microscopy (Figure 4.1). While Nano-11 could be 
readily observed inside BMDCs treated with DMSO (solvent for the inhibitors), EIPA 
(inhibits macropinocytosis) and chlorpromazine hydrochloride (inhibits clathrin-
mediated endocytosis) treated BMDCs had significantly decreased uptake of Nano-11. 
Dynasore (inhibits dynamin-mediated endocytosis) treated BMDCs had Nano-11 
attached to their cell membrane. However, the particles were not further internalized 
into the cells. Uptake of Nano-11 by BMDCs was not a ected by nocodazole (inhibits 
microtubules-mediated phagocytosis) treatment but CytoD (inhibits ac n-mediated 
phagocytosis) inhibited the internaliza on of Nano-11. Incuba ng the cells at     C, which 
blocks any active energy dependent endocytosis, completely blocked the uptake of 
Nano-11 by BMDCs. However, the confocal images indicate that EIPA, chlorpromazine 
hydrochloride, and dynasore disrupted the normal morphology of BMDCs to a variable 
degree, suggesting loss of viability. This would likely affect particle endocytosis as well.     
Internalization of Nano-11 was also evaluated by flow cytometry to obtain 
quantitative data and to complement the confocal microscopy. Single nonconjugated 
live BMDCs were differentiated based on the linear correlation of FSC-A and FSC-H, and 
live cells were identified with zombie violet staining. The amount of Nano-11 inside cells 
was measured based on the fluorescence intensity of AF647 from the cells (Figure 4.2). 







similar fluorescence intensity as DMSO treated cells, indicating no effect on Nano-11 
uptake (Figure 4.3). All the other treatments decreased the amount of  uorescence in 
BMDCs, with EIPA and     C treated cells having a more significant decrease.  
4.3.2 Tracing of intracellular Nano-11 
After internalization of a pathogen or other particulate matter by dendritic cells, the 
endosome will gradually mature as the pH decreases and in the end fuse with lysosomes, 
where the acidic environment and other proteolytic enzymes will degrade the cargo of 
the vesicles 4. To determine for the distribution of Nano-11 inside BMDCs over time, 
AF647-labeled Nano-11 was coincubated with BMDCs for different durations and the 
cells were then fixed, permeabilized and the intracellular lysosomes were stained with 
anti-LAMP-1 antibody to reveal the relative location of Nano-11-containig vesicles and 
lysosomes (Figure 4.4). Immediately after AF647-labeled Nano-11 was added to BMDCs 
(0 min), very few Nano-11 were observed by confocal microscopy, indicating that the 
particles had neither been internalized nor attached to the cell membrane yet. At 10 
min, most Nano-11 had formed a ring-like structure, possibly due to nanoparticles 
attaching to the cell membrane. By that time most of them have not been internalized. 
After 30 min, more Nano-11 was colocalized with lysosomes, and by 60 min all Nano-11 
was intracellular and overlapped with the fluorescence of lysosomes, indicating Nano-11 
has been taken up and shifted to intracellular lysosomes in BMDCs by that time.  
4.3.3 Effect of endocytosis blockage on inflammasome activation 
One of the stimulatory effects of Nano-11 on DCs is to induce the secretion of IL-1β. It 







proinflammatory cytokine from LPS primed BMDCs in a cathepsin B dependent manner 
371. To study the effect of different endocytosis blockage treatments on the induction of 
IL-1β secretion by Nano-11, cells were stimulated with LPS for one hour after various 
treatments and followed by the addition of Nano-11. BMDCs were further incubated for 
two days and then the supernatant was harvested for measurement of the IL-1β 
concentration (Figure 4.5). While neither LPS nor Nano-11 alone induced significant 
secretion of IL-1β, the combination of LPS and Nano-11 led to high level of IL-1β in the 
supernatant. EIPA, chlorpromazine hydrochloride, dynasore, and nocodazole did not 
a ect the amount the IL-1β in the supernatant while CytoD and incuba on at     C 
significantly enhanced the amount of IL-1β in the supernatant. 
4.4 Discussion 
Utilizing different inhibitors and physical condition, specific mechanisms involved in 
Nano-11 internalization were revealed in this study with both immunofluorescence and 
flow cytometry. Phagocytosis was found to contribute to the uptake of Nano-11 by 
BMDCs because blocking of actin with CytoD jeopardized Nano-11 uptake. However, 
microtubules, another form of cytoskeleton that was also reported to be involved in 
phagocytosis 390, did not play a role in Nano-11 internalization, as suggested by 
nocodazole treatment. Blocking of macropinocytosis, clathrin-mediated endocytosis, 
and caveolae-mediated endocytosis also inhibited the internalization of Nano-11, 
suggesting multiple routes the particle can use to enter the cells. The involvement of 
clathrin-mediated and caveolae-mediated endocytosis is consistent  with previous 







385,389,391,392. The fact that macropinocytosis also plays a role may contribute to the 
specific features of Nano-11, like the positive surface charge 371. Indeed in one study, 
blockage of macropinocytosis only decreased the cellular uptake of positively charged 
polystyrene nanoparticles similar in size to Nano-11 by 42%, suggesting positive 
nanoparticles in general have more mechanisms to enter the cells 393. A possible reason 
for this can be the electrostatic attraction force between those particles and the 
negatively charged cell surface brings the nanoparticles to the vicinity to or even makes 
them adsorbed on the cell membrane, making it easier for the di erent endocytosis 
mechanisms to internalize them. Incuba on of cells at     C almost completely blocked 
the uptake of Nano-11, indicating that it is an energy dependent process. Previously 
certain nanoparticles have been revealed to enter cells even at low temperature and it 
was speculated to be due to the direct permeabilization of the cell membrane by the 
nanoparticles 394. The absence of Nano-11 inside cells under that condition suggests that 
it does not cause significant damage to the cell membrane which is consistent with 
previous results indicating low cytotoxicity at the concentration used 371. 
Nano-11 was completely internalized and shuttled to the LAMP-1+ lysosomes 
within the time frame of 60 min. The maturation of nanoparticle-containing endosomes 
fusion with lysosomes is commonly reported for  nanoparticles 383,389. The time frame 
also correlated with that of PLGA nanoparticle, which was also found to appear in the 
lysosome within 60 min 395. Most nanoparticles are retained in the lysosome after being 
transported there and the biodegradable particles will  ultimately be digested there 







11-containing vesicles support the nanoparticle as a powerful tool for antigen delivery. 
In some cases, internalized nanoparticles can be transported back to the extracellular 
environment, either from early endosome or late endosome 388,389,398. However, this 
was not observed for Nano-11, as suggested by the ring-like fluorescence around the 
cells implying cell surface attached particles during the first 30 min of coincubation and 
the complete absence of fluorescence signal outside the cells by 60 min. Lysosomal 
escape of the nanoparticles into cytoplasm has also been reported 385,399 and again this 
was not observed for Nano-11, at least for the period of time we examined. Given that 
Nano-11 is based on biodegradable material phytoglycogen, the lack of exocytosis and 
lysosomal escape suggest the nanoparticles are likely to be degraded in the lysosome, 
further supporting their biocompatibility.  
Several other nanoparticles can activate the NLRP3 inflammasome, which 
involves the uptake of the particles followed by the leakage of cathepsin B from 
matured endolysosome into cytosol and an efflux of intracellular potassium 228,367,400–402. 
However, treatment of BMDCs with different inhibitors and physical condition that 
jeopardize Nano-11 uptake did not decrease the amount IL-1β secretion. For CytoD 
treated BMDCs and cells incubated under     C the amount of secreted IL-1β even 
increased. Two possible reasons may explain this. First, although the inhibitors reduced 
the amount of Nano-11 internalized, there may be other complementary pathways that 
may allow some level of particle uptake. This has been reported previously 386,403 and 
even in this experiment, we observed the amount of fluorescence associated with Nano-







CytoD treated BMDCs. IL-1β is usually first produced in a 31kDa pro form in the 
cytoplasm, which upon inflammasome cleavage will be secreted as the 17kDa active 
form 322. It is possible that some treatments caused certain level of cell membrane 
damage, which can lead to the release of non-cleaved pro-IL-1β into the extracellular 
environment. Since the ELISA kit we used here does not differentiate pro-IL-1β and 
active IL-1β, measurement of the molecular weight of IL-1β would need to be 
performed to answer this question.  
It is also worth pointing out that although our intracellular trackingof Nano-11 
showed it to be constrained in the lysosome and not present in the cytoplasm, for 
nanoparticle activation of  inflammasome, destabilization of the lysosome and release 
of cathepsin B into cytoplasm is often a critical step 228,367. This is well illustrated for the 
case of high aspect ratio (length divided by width) nanorods around 100nm in length 
that can induce lysosome destabilization. Their capability to activate inflammasome was 
directly related to lysosome damage 404. Indeed, IL-1β secretion induced by Nano-11 
was also found to be decreased by a CA-074, a cathepsin B inhibitor 371. In this case, it 
can be speculated that although Nano-11 itself does not escape to the cytoplasm, it may 
cause leakage of the lysosome to release smaller sized proteins like cathepsin B. Further 
experiments are needed to test such hypothesis.  
In conclusion, we have demonstrated here that phytoglycogen based adjuvant 
Nano-11 could be internalized by professional APCs through multiple routes. In addition, 
it would quickly shuttle to lysosomes after uptake, indicating itself as a powerful vaccine 







which requires a delicate manipulation of the physiological conditions of the particle-
containing vesicles. A more detailed knowledge on the effect of Nano-11 on these 
intracellular vesicles will help us better understand the immunostimulatory mechanism 









Table 4.1  Inhibitors and physical condition used to block particle uptake and their 
intended targets.  
Inhibitor  Mechanism  Concentration applied  
EIPA  Macropinocytosis  30 µg/mL  
Dynasore  Dynamin mediated endocytosis  25 µg/mL  
Chlorpromazine hyrdrochloride  Clathrin dependent endocytosis  20 µg/mL  
Cytochalasin D  F-actin mediated phagocytosis  2 µM  
Nocodazole  Microtubules mediated phagocytosis  10 µg/mL  












Figure 4.1 Immunofluorescence detection of Nano-11 uptake by BMDCs.  
Cells were treated with indicated endocytosis inhibitors and physical condition. Images 
are representative of four independent experiments and were taken under a confocal 









Figure 4.2 FACS gating strategy for detection of Nano-11 inside BMDCs.  
A sample of BMDCs without the feeding of fluorescently labeled Nano-11 as a negative 










Figure 4.3 FACS detection of Nano-11 uptake by BMDCs.  
Cells were treated with indicated endocytosis inhibitors and physical condition. (a) 
Representative data of four independent experiments. (b) Summarized effect of 
different inhibitors and physical condition on Nano-11 uptake. Mean fluorescence 
intensity (MRI) of each treatment is normalized to the MRI of DMSO treated cells.   








   
Figure 4.4 Intracellular kinetics of Nano-11.  
Relative location of Nano-11 and lysosomes was detected with immunofluorescence at 
different time points after coincubation. Data are representative of two independent 












Figure 4.5 Effect of endocytosis inhibition on IL-1β secretion by BMDCs.  
Amount of IL-1β in the supernatant after BMDC treatment with the indicated conditions 
and stimulation was measured by ELISA. Data are normalized to the value from cells 
treated with DMSO and stimulated with both LPS and Nano-11. Mean ± SEM of cells 
from four batches of BMDCs. Mean concentration of IL-1β from DMS /LPS/Nano-11 








CHAPTER 5. GENERAL CONCLUSION AND FUTURE DIRECTIONS 
In this study we demonstrated that Nano-11 is both an efficient vaccine delivery system 
and a good immunostimulator: 1) As an intramuscular delivery system, in vitro 
experiments showed Nano-11 could readily adsorb negatively charged antigens and 
enhance their uptake by DCs while in vivo experiments revealed that administration of 
Nano-11 adjuvanted vaccines could attract APCs to the vicinity of antigens and 
preferentially targeted antigens to highly immunopotentiating MigDCs travelling to the 
draining LN. 2) As an immunostimulator, Nano-11 recruit a variety of inflammatory cells 
to the injection site, including monocytes, macrophages, neutrophils, and eosinophils in 
addition to DCs. 3) Nano-11 also stimulates DCs by increasing the expression of 
costimulatory molecules on their surface and activating the NLRP3 inflammasome. In 
addition, studies also proved Nano-11 to be safe to use. In vivo fluorescence imaging 
revealed no systemic distribution of Nano-11 after administration, although the 
sensitivity of the technique may still be limited. Injected nanoparticles at the 
administration site were found to be rapidly cleared through phagocytosis by recruited 
macrophages. Collectively, this study showed phytoglycogen-based Nano-11 is a 
promising candidate for the next generation vaccine adjuvants.  







First, although inflammasome activation is a major stimulatory effect of Nano-11, 
the detailed process of how Nano-11 induces the assembly of NLRP3 inflammasome is 
still not well understood. This is reflected by two facts. First, we still do not know every 
step from Nano-11 internalization to the assembly of inflammasome, except that 
blocking of cathepsin B decreased the secretion of IL-1β. Second, some conflicting data 
have been collected regarding inflammasome activation by Nano-11. For example, the 
concentration of IL-1β in the supernatant of CytoD treated BMDCs was increased, 
though CytoD reduced Nano-11 uptake. Potentially the increase in IL-1β concentration 
can be caused by the release of cytoplasmic pro-IL-1β into supernatant. According to 
published studies, a number of events are involved in the activation of NLRP3 
inflammasome, including mitochondrial perturbation, reactive oxygen species 
generation, potassium efflux, and sodium influx, etc 405. Further testing the effect of 
these events on inflammasome assembly can help to delineate the procedure of Nano-
11-driven inflammasome activation.  On the other hand, since the ELISA used in this 
study does not differentiate pro-IL-1β from inflammasome cleaved IL-1β, other 
methodologies like Western blot that can determine the size of the cytokine should be 
utilized. An extensive testing of both intracellular and supernatant IL-1β will shed light 
on some of the previously inconsistent IL-1β ELISA results (e.g. CytoD treated BMDCs) 
and confirm whether the conclusion we will draw from the new experiments is truly due 
to their impact on the assembly of inflammasome machinery. These experiments should 







Second, Nano-11 has been tested with two model antigens, OVA and rPA, in this 
study, but whether Nano-11 can be applied to a broader range of antigens is still a 
question that needs to be answered. Nano-11 has been demonstrated to specifically 
adsorb negatively charged antigens but not positively charged antigens371. Given that 
the two antigens we tested here are both negatively charged proteins, for which Nano-
11 is speculated to have a stronger delivery effect to APCs, whether the nanoparticle 
can also help enhance the immune response for positively charged antigens is 
something that requires in vivo testing. On the other hand, codelivered cargos other 
than proteins antigens, like nucleic acid, should also be evaluated for formulation with 
Nano-11. This can show if Nano-11 can also serve as an adjuvant for DNA vaccines.  
Third, Nano-11 needs to be tested in more animal models other than mice 
before any foreseeable clinical trials. Animals larger than mice, like rabbits, dogs, and 
pigs can be good candidates. Purdue University has a Pig Translational Pharmacology 
(PTP) unit that employs state of the art Pigturn-Culex-L® housing. It can self adjust the 
cage along with movement of pigs to allow a real time collection of blood samples 
through an intravenous catheter in a stress-free manner. In this way, analysis of 
cytokines, acute phase proteins, liver enzymes, creatinine, and urea in the first few 
hours and days after injection can also be conducted, in addition to testing the immune 
response toward Nano-11 adjuvanted vaccines. This would allow us to have a clearer 
view on the effect of Nano-11 on early phase immune reaction and the recipients’ 
overall physiological conditions. Given the comparable adjuvanticity between Nano-11 







vaccines can be applied in this experiment. The maximum dosage of aluminum adjuvant 
allowed in human vaccines is 0.85 mg Al per dose 21, which translates to 1.89 mg of 
aluminum hydroxide. In this case a dosage of around 2 mg Nano-11 can be tested in pigs. 
In this case, pigs would be a good animal model to conduct the next round of animal 
study for Nano-11.  
Fourth, in this study Nano-11 adjuvanted vaccines were administered through 
intramuscular injection. In the following studies, Nano-11 should also be tested with 
mucosal routes. This could induce both systemic response and mucosal protection, 
offering immunity to many pathogens at their port of entry into the body. Adsorption of 
soluble antigens onto Nano-11 would render them into particulate form, and in this way 
it is expected they would be more easily picked by M cells and transported to the 
underlying lymphoid tissue. The immunostimulatory nature of Nano-11 could then also 
help to activate the antigen-containing APCs once the vaccine reaching the lymphoid 
tissue. In this case, a positive mucosal immunostimulation should be expected for Nano-
11 formulated vaccines. A reasonable experiment to start would be a Nano-11 
adjuvanted intranasal vaccine due to its ease of operation, with model antigens from 
mucosal pathogen like influenza. Antigen specific immunoglobulin, especially antigen-
specific IgA in the mucosal route and antigen-specific IgG in the serum will be measured 
to assess the immunopotentiation efficiency of both mucosal and systemic response by 
Nano-11. Immunized mice can also be challenged with the corresponding pathogens 







Last but not least, the type of immune response activated by Nano-11 needs to 
be better characterized.  To have a more detailed appreciation of what types of CD4 T 
helper (Th) cells are activated by Nano-11, splenocytes of immunized mice can be 
restimulated in vitro with the antigen and concentration of signature cytokines of 
different types of Th cells (IFNγ for Th1, IL-4 for Th2, and IL-17 for Th17) can be 
measured with ELISA. To test whether cell-mediated immune response is induced by 
Nano-11, C57BL/6 mice can be immunized with Nano-11 adjuvanted OVA and the 
percentage of OVA-specific CD8 T cells can be measured with fluorescently labeled 
SIINFEKL-H-2 Kb-tetramer through flow cytometry. After the type of immune response is 
better characterized, modification of Nano-11 can be attempted to see if this can 
achieve an even higher immunopotentiation and more mixed response – i.e., both 
humoral and cell-mediated immune responses.  This can be attempted in two ways. First, 
Nano-11 can be coformulated with other immunostimulators, e.g. TLR agonists. This is 
the same philosophy as the design of current second generation vaccine adjuvants with 
the combination of one vaccine delivery system and one immunostimulator. In such a 
formulation, the particulate nature of Nano-11 enables it serve more like a delivery 
system while the strong stimulatory effect of TLR agonists can ensure that the induced 
response is both potent and mixed, since it has been shown that TLR agonists induce 
both humoral and cell-mediated immune responses 14. On the other hand, 
phytoglycogen, which Nano-11 is based on, has high flexibility leniency for surface 
functionalization. Such modifications have resulted in similar sized phytoglycogen 







In this case, a full-scale screening of other currently available phytoglycogen 
nanoparticles may reveal additional candidates of vaccine adjuvants, and it is possible 
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